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1 Abstract 
 
The use of viral vectors as delivery vehicles for therapeutic genes (gene therapy) is being 
investigated and improved since two decades. Despite exciting advances and promising 
results in animal studies and clinical trials, technical refinements are still needed to improve 
efficiency and safety of gene transfer. One of the most popular vector types derives from 
adeno associated virus of type 2 (AAV2). This virus has attracted the interest of gene 
therapists being safe, easy to produce at high titers and offering the possibility to target a 
plethora of cell types and to maintain detectable levels of transgene expression for long times. 
However, two major limitations hamper the use of this vector type. First, the broad tropism of 
AAV means that vectors are rather unspecific and therefore likely to infect neighboring 
tissues. Second, high seroprevalence in human populations of antibodies directed against 
wtAAV2 capsids reduces or abolishes transduction rates in individuals with pre-existing 
immunity. 
The goal of my work was to address these two major issues and develop new methods to 
engineer AAV capsid variants with increased target selectivity and decreased antibody 
recognition. 
Within a first project, I established for the first time a straight-forward in vitro protocol for the 
selection of viral mutants with increased selectivity for a melanoma cell line (BLM) out of a 
combinatorial viral library. The selection procedure consisted of a negative selection step on 
non-target cells and a positive selection step on BLM cells. Selected mutants showed almost 
wt levels of infectivity on BLM cells while transducing several tested non-target cells with a 
significantly lower efficiency, resulting in a up to 3.7-fold increase of target specificity. 
Within the second project I generated a novel AAV2 capsid library by randomizing five 
amino acid residues that had been previously reported to play a role in antibody docking to 
the viral shell. Screening this library for particles that remained infectious despite pre-
incubation with neutralizing antibodies allowed the isolation of several capsid variants that 
remained highly infectious even in the presence of antibody concentrations that completely 
neutralize wtAAV2.  
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2 Zusammenfassung 
 
Die Verwendung viraler Vektoren als Genfähren zum Transfer therapeutische Gene in 
menschliche Zellen wird seit über zwei Jahrzehnten erforscht. Trotz aufregender Neuerungen 
und vielversprechender Ergebnisse aktueller Tierexperimente und klinischer Studien muss die 
Sicherheit und Effektivität dieser neuen Technologie noch weiter verfeinert werden. Das 
Adeno-assoziierte Virus vom Serotyp 2 (AAV2), ein sicheres, effektiv herstellbares Virus ist 
einer der beliebtesten Vektoren zum Einsatz in der Gentherapie, da es eine stabile 
Genexpression in einem breiten Spektrum verschiedener Zelltypen über lange Zeit 
ermöglicht.  
Zwei Nachteile behindern den Einsatz dieses Virus jedoch in besonderem Maße: Auf der 
einen Seite zieht der breite Tropismus bei systemischer Gabe die unspezifische Transduktion 
von Geweben nach sich, die nicht infiziert werden sollen. Zum Zweiten ist ein Großteil der 
Menschheit schon unbemerkt mit dem Virus in Kontakt gekommen und verfügt über 
neutralisierende Antikörper, welche die Transduktion der Zielzellen durch die Genfähren 
verhindern.  
Ziel der beiden Projekte meiner Arbeit war die Entwicklung neuer kombinatorischer 
Strategien um die oben genannten Einschränkungen zu beseitigen. 
In einem Projekt wurde ein in-vitro Protokoll entwickelt, mit dem Virusmutanten mit 
gesteigerter Spezifität für eine Melanomzelllinie (BLM) aus einer kombinatorischen 
„Viruslibrary“ selektiert werden konnten. Das Protokoll besteht aus einem 
Negativselektionsschritt auf Fibroblasten und einem anschließenden Positivselektionsschritt 
auf BLM-Zellen. Die selektierten Mutanten zeigten mit Wildtyp vergleichbare Infektionslevel 
auf BLM-Zellen und signifikant herabgesetzte Transduktion der Fibroblasten und weiterer 
Nicht-Zielzellen.  
Im zweiten Projekt habe ich eine neuartige „AAV2-Kapsidlibrary“ generiert, in der fünf zuvor 
als wichtig für Antikörperbindung charakterisierte Aminosäurepositionen vollständig 
randomisiert wurden. Nach vier Selektionsrunden mit neutralisierendem Serum konnte ich 
mehrere Mutanten isolieren, die trotz Anwesenheit von Serumkonzentrationen infektiös 
waren, welche den Wildtyp vollständig neutralisierten.  
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3 Introduction 
3.1 Human gene therapy 
Delivery of therapeutic genes to diseased tissues (gene therapy) holds the potential to heal a 
broad range of genetic and non-genetic pathologies by correcting genetic defects or by 
controlling the cellular metabolism by regulating gene expression. Different methods to bring 
foreign DNA into human cells ex vivo or in vivo are being developed. These techniques can 
be divided in two main groups. Non-viral methods exploit the possibility to deliver naked 
DNA/RNA or to couple this genetic information with different compounds (e.g. coating the 
nucleic acid with polyethylenglycole or lipofectamine). The other possibility is to use viruses 
as delivery vehicles. Until today, more than 1340 clinical trials have been conducted 
worldwide (Figure 1), aiming at delivering a plethora of different genes to address a wide 
variety of diseases. 
 
Figure 1: Overview over clinical trials with gene therapy vectors (taken from 
http://www.wiley.co.uk/genetherapy/clinical/) 
Over 65% of clinical trials worldwide use viral vectors as vehicles. Natural viruses have 
evolved to deliver their genetic cargo into host cells and these characteristics can be exploited 
to deliver therapeutic genetic material in gene therapy approaches. However, before they can 
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be successfully employed, natural viruses need to be adapted to medical usage. In particular, 
two aspects are fundamental: safety and efficacy. 
In 1999, Jesse Gelsinger, an 18 years old Ornithine Transcarbamylase (OTC) deficiency 
patient died in Pennsylvania, USA, after treatment with a high dosage of adenoviral vector 
containing a normal copy of the OTC gene. The following investigation allowed to conclude 
that the subministred vector triggered a severe immune reaction leading to multiple organ 
system failure (Somia and Verma 2000). 
In 2002, a retroviral vector containing the common γ-chain gene for the cytokine receptors IL-
2R, IL-4R, IL-7R, IL-9R and IL-15R was inoculated to ten X-linked severe combined 
immunodeficiency (X-SCID) patients. X-SCID normally leads to death within the first year of 
life. More than seven years later, 3 out of 11 patients have developed T-cell Leukemia as a 
consequence of the vector administration. One of them died of the cancer. The others live 
without SCID symptoms, two of them still fighting against leukemia (Cavazzana-Calvo et al. 
2005; Cavazzana-Calvo and Fischer 2007). This example emphasizes the promises but also 
the challenges of this technology. 
Advances in understanding diseases at molecular level and a better understanding of strengths 
and weaknesses of viral vectors is improving success rates of gene therapy protocols. Since 
the issues in this context are peculiar for each different vector type, the following paragraphs 
will focus on summarizing the relevant aspects with regard to the viral vector that has been 
the subject of my work: the adeno associated virus (AAV). 
 
3.2 Adeno associated virus  
3.2.1 Classification of adeno associated viruses 
Adeno associated viruses (AAV) are members of the family of the parvoviridae. These non-
enveloped viruses consist of a small icosahedral capsid with a diameter of 18-26 nm. The 
capsid contains a single-stranded DNA genome of approximately 4.7 kilobases. Parvoviruses 
can be divided into vertebrate- and insect-infecting viruses, classified as parvovirinae and 
densovirinae respectively. Human parvoviruses are not known to cause any disease except for 
erythrovirus B19 (Brown 2000) that was isolated by J. R. Pattison in the 1970s and can cause 
erythema infectiousum, hydrops fetalis and abortion. The first isolate of AAV was identified 
as contaminant in a simian adenovirus 15 preparation and therefore named adeno associated 
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virus. To date, thirteen other serotypes and more than 100 variants have been isolated in 
humans, other primates, rodents, or invertebrates. The serotypes have different levels of 
sequence homology causing differences in host and cell tropism and recognition by antibodies 
(Lukashov and Goudsmit 2001; Gao et al. 2002; Calcedo et al. 2009). In addition, AAV is 
classified in the genus of dependoviruses and in contrast to autonomous parvoviruses it 
requires for replication external helper functions that can be supplied by other viruses (e.g. 
adenovirus, herpes simplex virus, vaccine virus, human cytomegalovirus or papilloma virus) 
or by physical or chemical factors (e.g. UV- or γ-radiation, heat shock, cancerogenic 
compounds) (Atchison, Casto et al. 1965; (Richardson and Westphal 1981; Schlehofer et al. 
1986; Yalkinoglu et al. 1991). AAV2, the best analyzed serotype, was found in an adenovirus 
12 contamination (Hoggan et al. 1966). Its atomic structure is resolved to three angstrom (Xie 
et al. 2002) (see 3.2.3). 
 
3.2.2 Genome organization of AAV2 
In 1982, the complete nucleotide sequence of AAV2 was determined (Srivastava et al. 1983). 
The single stranded DNA genome consists of 4675 base pairs (bp) coding for two open 
reading frames (ORFs). The cap gene codes for three structural proteins that build the viral 
shell while the rep gene encodes four non-structural proteins needed for replication and 
encapsidation of the viral genome. The ORFs are flanked by 145 bp long inverted terminal 
repeats (ITRs) that build a T-shaped hairpin structure at both ends of the viral genome and are 
used as origin of replication, as packaging signals and for the integration or excision of the 
viral DNA into the host genome (McLaughlin et al. 1988; Kotin et al. 1990)(see Figure 2).  
The four multifunctional proteins Rep78, Rep68, Rep52 and Rep40 (named according to their 
molecular weight in kilodalton) are expressed under control of promoters p5 (Rep78; Rep68) 
and p19 (Rep 52; Rep 40), named after their position in the genome, which was divided into 
100 map units. Rep expression results in four proteins, Rep68 and Rep40 being splice variants 
of their larger counterparts. All Rep proteins share helicase and ATPase activities, while 
Rep78 and Rep 68 also have site specific DNA-binding, and endonuclease activities (Im and 
Muzyczka 1990; Berns and Giraud 1996; Smith and Kotin 1998; Collaco et al. 2003). Rep72 
and Rep68 contain nuclear localization signals essential for replication, transcription and site-
specific integration into the host genome (Cassell and Weitzman 2004) while Rep 52 and 
Rep40 are responsible for helicase-dependent packaging of the viral genome into the 
preformed capsid through pores (Becerra et al. 1985; Wistuba et al. 1997; Dubielzig et al. 
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1999; King et al. 2001; Bleker et al. 2005). Rep proteins also control the splicing of cap and 
their own expression in the absence of helper effects by repressing p5 and p19 transcription 
(Pereira et al. 1997; Kronenberg et al. 2001; Qiu and Pintel 2002). 
 
 
Figure 2: Organisation of the AAV2 genome and gene products.  Two ORFs rep and cap are 
expressed under the control of three promoters p5, p19 (rep) and p40 (cap) named after their 
map unit position in the 4675 bp genome that is divided into 100 map units.  The ORFs are 
flanked by inverted terminal repeats . A shared poly adenylation signal at unit position 96 is 
shared by all transcripts, while use of alternative splicing, alternative promoters and  
alternative start codons results in four rep genes, responsible for replication and three cap 
genes that built up the viral shell. Open reading frames are shown in cylinders, untranslated 
regions as solid lines and introns as kinks.  
Three structural proteins VP1, VP2 and VP3 that share the same C-terminus are expressed 
from the cap ORF under the control of a promoter at map position 40 (p40). With respective 
molecular masses of 87, 72 and 62 kilodaltons (kDa), the three proteins are translated from 
two transcripts that arise from alternatively splicing of the cap gene. The longer one is 
translated into VP1, the largest of the three proteins that carries a phospholipase A2 domain at 
its N-terminus required for efficient infection (Zadori et al. 2001; Girod et al. 2002). VP2 and 
VP3 are translated from the shorter transcript from two separate start codons that supposedly 
have different translational activity. This gene architecture results in a VP1, 2 and 3 protein 
production at a 1:1:8 ratio respectively, which provides the appropriate proportion of capsid 
subunits (Becerra et al. 1988) to form a viral capsid of 60 subunits which is assembled with T 
= 1 icosahedral symmetry (Xie et al. 2002) by 5 VP1, 5 VP2 and 50 VP3 subunits. The 
numbering of amino acid positions in capsid proteins refers to the VP1 counting in the 
following. 
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3.2.3 Capsid structure 
Recently the atomic structure of AAV-2 has been determined to 3 Å resolution by x-ray 
crystallography. Each viral capsid is composed of 60 subunits arranged with T=1 icosahedral 
symmetry  of the three structural proteins VP1, VP2, and VP3 (Xie et al. 2002). They share 
overlapping sequences and differ only at 
their N-termini but these portions could 
not be resolved in the 3-D structures due 
to low electron density. Between the 
strands of a β-barrel core (Fig. 2) which is 
highly conserved among parvoviruses, 
large loop insertions are found that share 
only low similarity among the parvovirus 
family. These loops comprise two-thirds 
of the capsid structure and constitute the 
capsid surface features that interact with 
antibodies and cellular receptors. 
Three of these loops contribute to the formation of the 3-fold-proximal peaks, which cluster 
around the 3-fold symmetry axis. In the valleys separating the three peaks of one 3-fold axis, 
clusters of positive charges are located, which are implicated in receptor binding. Mutational 
analyses have identified these locations being involved in binding to the primary receptor of 
AAV-2 (Wu et al. 2000). The basic aa R487, R585, R588 and H509, which are at the side of 
the peak seem to play a crucial role (Wu et al. 2000; Grifman et al. 2001; Xie et al. 2002; 
Opie et al. 2003). Mapping of antibody binding epitopes (Wobus et al. 2000) (Huttner et al. 
2003) have suggested the importance of the 3-fold proximal peaks not only in receptor 
binding, but also for the recognition of the viral particles by antibodies. Moreover, it is 
possible that other important viral functions are also located at this prominent feature. 
Since the VP1 and VP2 regions of the capsid proteins are located within the lumen of the viral 
particle (Kronenberg et al. 2005), all virus:cell interactions that take place before entry and 
the interations between capsid and antibodies only depend on the surface of the VP3 protein. 
 
 
Fig. 2: 3D structure of the VP3 capsid 
protein (Xie et al. 2002). See text for 
details. Blue numbers and lines indicate 
the symmetry axes. 
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Figure 3: Surface topology of AAV-2 (Xie 
et al. 2002). The capsid is colored 
according distance from the viral center.  
 
3.2.4 Infection biology of AAV2 
Before AAV2 enters a cell, it contacts the 
cell surface several times and binds to its 
primary receptor heparan sulfate 
proteoglycan (HSPG) (Summerford and 
Samulski 1998; Seisenberger et al. 2001). 
Residues responsible for HSPG binding 
have been described to be R484; R487; K532; R585 and R589 (Kern et al. 2003; Opie et al. 
2003). For efficient uptake, the virus must also interact with additional secondary receptors. 
Human fibroblast growth factor receptor 1, hepatocyte growth factor receptor, laminin 
receptor, the integrins αvβ5 or α5β1  have been proposed as secondary receptors (Qing et al. 
1999; Summerford et al. 1999; Kashiwakura et al. 2005; Akache et al. 2006; Asokan et al. 
2006) but a role of other molecules cannot be excluded.  
After binding its receptors, the virus can enter the cell by receptor-mediated, dynamin 
dependent endocytosis through clathrin coated pits (Duan et al. 1999; Bartlett et al. 2000). 
The exact events leading to internalization however are not completely understood. After 
moving along microtubules and microfilaments towards the nuclear area (Douar et al. 2001), 
AAV2 particles escape from endosomes after their acidification and accumulate in the 
perinuclear area (Bartlett et al. 2000). Rac1 and the PI3K pathway play an essential role in the 
efficiency of this step of infection (Sanlioglu et al. 2000). 
It is not clear whether only genomes, protein-DNA complexes or whole particles of AAV2 
enter the nucleus (Sanlioglu et al. 2000; Lux et al. 2005). Due to their small diameter, whole 
particles could enter through nuclear pore complexes (NPC) and an interaction of the viral 
capsid with a nuclear shuttle protein has been reported (Qiu and Brown 1999). However, NPC 
independent pathways have been suggested by other experimental data (Hansen et al. 2001). It 
is also important to note that different molecular pathways could be used for infection 
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depending on cell type, virus load, presence or absence of helper function and kind of helper 
function (Hansen et al. 2001; Xiao et al. 2002; Lux et al. 2005).  
In the absence or helper effects, AAV2 converts its single stranded DNA into a double 
stranded form and integrates it into the host genome or stay in an episomal state. Integration 
occurs only in the presence of Rep proteins and mostly at the so called AAV site 1 (AAVS1) 
on chromosome 19 (Kotin et al. 1992; Nakai et al. 2001) which resides rep binding element 
and terminal resolution site sequences identical to those of AAV2 (Weitzman et al. 1994; 
Linden et al. 1996). 
After co-infection with helper viruses or in the presence of a helper effect like chemical or 
physical stress of the cell, integrated provirus can be rescued and initiate a lytic life cycle 
(Berns and Giraud 1996). In this case, a double stranded genome is produced to induce gene 
expression and replication (Goncalves 2005).  
. 
3.3 AAV as a gene therapy vector 
3.3.1 Production of recombinant AAV2 vectors  
In our days, the genomes of AAV2 and other serotypes are available on plasmids. In gutless 
vectors, the viral genome is replaced by a desired transgene of up to 6 kb, only flanked by 
viral ITRs that are needed for packaging and gene expression. Producer cells (e.g. HEK293, 
transgenic for adenoviral genes E1A, E1B) are transfected with plasmids providing AAV rep 
and cap genes plus additional helper functions. For production of viral libraries or cloning 
constructs of wtAAV2, the rep and cap genes must be flanked by ITRs. When gutless vectors 
are produced, only the transgene, added to the transfection mixture on an additional plasmid is 
flanked by ITRs (see Figure 4)(Laughlin et al. 1983; Rolling and Samulski 1995; Xiao et al. 
1998; Collaco et al. 1999; Allen et al. 2000; Grimm et al. 2003).  
The viral progeny can be harvested by freeze and thaw cycles and purified on affinity 
columns (e.g. heparin-columns), iodixanol- or CsCl- gradients (Hermens et al. 1999; 
Zolotukhin et al. 1999; Anderson et al. 2000). Preparation quality and yield can be quantified 
by quantitative polymerase chain reaction (qPCR) and enzyme linked immunosorbent assay 
(ELISA). 
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Figure 4: Production of adeno virus free rAAV vectors.  HEK293 cells are transfected with 
three plasmids carrying rep and cap genes without ITRs in trans on a helper plasmid, 
adenoviral helper functions on a adenoviral plasmid and the desired transgene flanked by ITRs 
on a vector plasmid. The virions package within 48 hours and can then be isolated and 
purified. 
Since second strand synthesis is a limiting step for gene expression, self-complementary 
genomes have been developed (McCarty et al. 2001), enhancing the expression rate in vitro 
and in vivo but limiting the size of the transgene to half the size. Other optimizations have 
been made to enhance purity and scale of AAV preparations during the last years (Blouin et 
al. 2004; Van Vliet et al. 2008). 
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3.3.2 Characteristics of AAV  
Depending on the aims of gene therapy trials, requirements for a vector can differ. Therefore, 
it is hard to judge general advantages and disadvantages of some of AAV´s features. Anyway, 
I want to point out AAV-specific characteristics in this chapter to reveal its adequacy for gene 
therapy. 
The first and most important requirement for a gene therapy vector is safety. No human 
disease could be related to AAV serotypes and the only known disease is caused by human 
parvoviral pathogene iserythrovirus B19 (Brown 2000). AAV has been used in over twenty 
clinical trials conducted to target a variety of diseases and to date no severe toxicity or 
immune reactions (see 3.3.3) have been associated with vector subministration. With helper 
virus free production methods and gutless vectors, AAV vectors are not contaminated with 
other viruses and cannot replicate themselves (Samulski et al. 1987). They integrate 
specifically at AAVS1 site in vitro if rep is given in trans (Huttner et al. 2003). Integration ath 
this site does not perturb host cell biology as it can be the case for retroviruses. However, 
recently some studies have reported occasional events of non-specific chromosomal 
integration. In vivo, stable, circular double-stranded episomes allocate the majority of wild-
type AAV DNA (Kotin et al. 1992; Duan et al. 1998; Nakai et al. 2001; Miller et al. 2002; 
Philpott et al. 2002; Schnepp et al. 2005). 
AAV vectors are capable of long term transduction of targeted tissues. Expression of vector 
transgene was detectable up to over six years after application in some cases (Romano 2005; 
Warrington and Herzog 2006). 
Due to the availability and heterogeneity of different AAV serotypes and variants a broad 
range of target organs like brain, heart, muscle, liver and lung; dividing and non-dividing cells 
can be targeted (Flotte et al. 1993; Kaplitt et al. 1994; Podsakoff et al. 1994; Alexander et al. 
1996; Kaplitt et al. 1996; Fisher et al. 1997; Manno et al. 2006).  
The broad tropism of AAV vectors might be explained by the wide diffusion of their receptors 
(e.g. HSPG and integrins) on the surface of many cell types. While this allows the use of 
AAV vectors for a large number of therapeutic applications, it represents a disadvantage for 
applications requiring specific and selective transduction of target tissues. A typical example 
is cancer therapy with suicide genes, where unspecific transduction of neighboring tissues 
would cause severe collateral damage. In addition, unspecific vectors are dispersed in 
undesired organs and therefore higher doses of the vector must be applied. 
Introduction 
12 
 
Another limitation of AAV vectors is their packaging capacity of 5-6 kb. Recently, different 
techniques showed that larger transgenes can be split and delivered by so called “trans-
splicing vectors” (Dong et al. 1996; Grieger and Samulski 2005; Ghosh et al. 2007). 
 
3.3.3 Immune responses to AAV vectors  
Up to 96% of humans are seropositive to AAV2 and up to 60% have neutralizing antibodies 
(Nabs) against the virus. The prevalence of Nabs is spread worldwide but depends on age, 
country, and ethnic group generally being highest in Africa for common serotypes (Erles et al. 
1999; Calcedo et al. 2009). Although non-hazardous for the patient, neutralization of gene 
therapy vectors in the blood would prevent transduction of target cells or organs (Scallan et al. 
2006; Lin et al. 2008). Some newly isolated, non-human viruses like AAV8 or AAVrh32.33, 
have a much lower prevalence of neutralizing antibodies (less than 10% in the human 
population), do not cross react with anti-AAV2 antibodies and have therefore attracted the 
interest of the scientific community as alternatives to circumvent pre-existing immunity (Gao 
et al. 2002; Scallan et al. 2006; Calcedo et al. 2009). However, not all serotypes are suitable 
for human gene therapy due to low infectivity or undesired tropism.  
Animal studies also suggest, that even naïve patients would develop antibodies against any 
serotype or variant after a first treatment. Re-administration of AAV is therefore restricted to 
serotypes that do not cross-react with antibodies against the serotype used in the first 
treatment and that can provide sufficient transduction rates in the targeted tissue (Halbert et al. 
2000; Moskalenko et al. 2000). For chronic diseases and long-time treatment, immunologic 
reactions can be suppressed efficiently for every consecutive treatment (Manning et al. 1998). 
This treatment however is cumbersome, uncomfortable and risky for the patient. Quarantine is 
required since infection with other pathogens during treatment can lead to serious 
complications without an intact immune system.  
In contrast to other viruses, AAV has minimal inflammatory potential and does not trigger 
severe immune responses. AAV2 is able to infect dendritic cells but due to an unknown post-
entry block, they are not able to efficiently activate a T-cell response (Zhang et al. 2000). The 
cellular immune response against AAV was disregarded for years until liver inflammation 
was observed in patients after AAV2 treatment (Manno et al. 2006). Because human is a 
natural host of AAV2 and liver damage was not described in mice, it was suggested that 
cellular immune response was triggered by former co-infections of the patients with wtAAV 
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and immune activating helper viruses that occurred incidentially before the begin of therapy 
(Mingozzi et al. 2007). However, cellular immune responses against the capsid have been 
reported in human and animal studies (Manno et al. 2006; Mingozzi et al. 2007; 
Vandenberghe and Wilson 2007; Wang et al. 2007).  
Since gutless AAVs do not express viral capsid or replicative genes, activation of CD8+ T-
cells after infection of cells and degradation of the capsid must occur through exogenous 
antigen presentation. It has been demonstrated that AAV-capsid specific T-cells do not lyse 
rAAV-infected cells (Li et al. 2007; Li et al. 2007; Wang et al. 2007). In addition, 
immunologic reactions against endogenous transgenes have not been reported, indicating that 
effective long-time expression can be reached with AAV vectors by immunosuppression 
during treatment until the clearance of vector capsid is complete.  
 
3.3.4 Clinical trials with AAV vectors 
Being considered a safe and efficient vector with long-time gene expression potential, AAV is 
being adopted in an increasing number of clinical trials aiming to cure a wide spectrum of 
diseases like Parkinson, Canavan`s disease, α1-antitrypsin deficiency, rheumatoid arthritis, 
cystic fibrosis and Hemophilia B (Goncalves 2005).  
The first disease that was treated with AAV was a phase I study of patients with mild lung 
disease of cystic fibrosis transmembrane conductance regulator deficiency (Flotte et al. 1996). 
The deficiency leads to chronic inflammation and lung damage which lead to early death 
because of loss of respiratory function. Clinical phase I and II trials have been conducted 
today with promising outcome for the future but no therapeutically relevant long-time 
expression has been reported so far.  
Interesting results are announced from trials concerning hemophelia B (blood factor IX 
deficiency), a monogenic defect leading to failure in blood clotting. Tested doses of 
administered vectors were not causing immunologic side effects but were also too low to raise 
serum factor IX levels above 1% of normal, the minimal concentration needed for effective 
blood clotting. Newer results show however that increasing vector doses and switching from 
intramuscular to intraportal administration leads to liver transduction and therapeutical 
relevant levels of factor IX expression but also to liver inflammation accompanied by decline 
of factor IX levels after eight weeks (Manno et al. 2006). 
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Similar results are reported from lung disease trials against α-1 antitrypsin deficiency (ATT). 
Transient gene expression was reported, but higher levels are needed for therapeutic treatment 
(Brantly et al. 2006).  
In Leber congenital amaurosis (LCA), a severe retinal dystrophy causing blindness or severe 
visual impairment before the age of 1 year, AAV therapies have already achieved promising 
results. One form of the disease, LCA2, is caused by mutations in the retinal pigment 
epithelium-specific 65-kDa protein gene (RPE65). No severe side effects were diagnosed and 
patients reported increased sensitivity of sight after AAV-RPE65 treatment (Jacobson et al. 
2006; Hauswirth et al. 2008; Maguire et al. 2008; Cai et al. 2009).  
Lately, a patient treated with an AAV2 vector in a trial concerning rheumatoid arthritis died 
but the following investigation allowed to demonstrate that the death was not related to the 
administered vector  but as consequences to anti-TNF therapy drug treatment that caused 
disseminated histoplasmosis in conjunction with retroperitneal hematoma instead (Kaiser 
2007). 
Anti-cancer gene therapies studies have not yielded broad success in the clinic. However, 
since being promising for future therapies, some of the general ideas are listed in the 
following paragraph.  Anti-cancer gene therapies can be classified by different approaches 
used. Immunotherapies aim at enhancement of tumor cell recognition by the immune system. 
Malignant cells can be loaded in vivo or ex vivo with immunostimulatory molecules (e.g. 
tumor necrose factor α (TNF-α) or CD 40 ligand). Also vaccination of dendritic cells with 
tumor antigens or ex vivo transduction of T-cells with tumor specific T-cell receptors activate 
the immune system and increase recognition of tumor tissue (Nestle et al. 2005; Morgan et al. 
2006; Aiuti et al. 2007; Alexander et al. 2007). Some naturally occurring oncolytic viruses 
and their laboratory derived relatives selectively replicate in cancer cells, causing cell death 
and infecting neighboring cells. However, non of the tested viruses was applicable 
systemically but reported effects were always local (Hu et al. 2006; Aiuti et al. 2007). Suicide 
gene therapy is a promising approach to effectively abolish tumor cells, especially for 
metastatic tumors that are hard to treat with irradiation, surgery or local drug application. The 
concept is to deliver suicide genes exclusively to tumor cells or tumor vascular system cells to 
directly kill the tumor cells or cut the tumor cells off from oxygen and nutrients with a 
prodrug that is applied systemically after infection of the target cells with the suicide gene 
(e.g. herpes simplex thymidine kinase (Hstk) and glanciclovir, a prodrug that becomes toxic 
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only after being metabolized by Hstk)  (Plautz et al. 1991; Niculescu-Duvaz and Springer 
2005; Alexander et al. 2007).  
In summary, AAV clinical trials for several diseases are at a stage where safety has been 
proven and vector doses need to be adjusted to gain therapeutic relevant gene expression 
levels (Romano 2005; Warrington and Herzog 2006). Optimization of vector construction for 
effective targeting, immune escape and long time transgene expression of the transgene has to 
be refined and immune modulation during treatment considered.  
 
3.4 Engineering of AAV vectors  
The growing understanding of mechanisms underlying the infectious biology of the AAV 
capsid and its role in the infectious process have paved the way for efforts aiming at 
engineering viral particles at molecular level in order to tailor them with optimized 
characteristics required by the envisioned application. 
To control packaging efficacy, host immune reactions against AAV, tropism, specificity, 
infectivity, genome size, intracellular trafficking and gene expression of AAV are major goals 
that would dramatically contribute to the breakthrough of AAV vectors in clinical routine.  
Vector tropism depends on the surface architecture and chemical composition of the capsid 
surface. The structures presented to the external surface of the viral shell mediate interactions 
with the humoral immune system and with cellular receptors responsible for the binding and 
uptake of the particle into the cell. These structures can be chemically or genetically modified 
to modify the way they interact with the host environment. Viral particles can be engineered 
by two major approaches: rational approaches and evolutionary approaches.  
3.4.1 Rational approaches 
In a rational approach, scientists make an educated guess which amino acids or protein 
domains are to be changed in a defined way. Substitutions, insertions or deletions are chosen 
on purpose to yield a specific, intended phenotype of the generated mutants. 
On the on hand, wtAAV vectors were coated with chemical reagents such as 
polyethylenglycol or biological molecules, e.g. bispecific antibodies or avidin linked ligands 
to change their tropism (Bartlett et al. 1999; Ponnazhagan et al. 2002). Although showing 
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altered tropism in vitro, critics argue that binding of coated reagents might not persist in vivo 
and attached molecules could interfere with post entry steps of the vector. 
In rational genetic approaches, amino acids have been substituted or peptides have been 
inserted into the capsid. A single-chain antibody against human CD34 was genetically 
inserted at the N-terminal region of capsid proteins in an effort to target hematopoietic 
progenitor cells (Yang et al. 1998). In another case, both genetical modification and chemical 
coupling were combined: Ried et al. inserted an immunoglobulin (IgG) binding domain at 
position 587 of the capsid protein to enable rAAV to bind different antibodies via their Fc 
regions. The Fab region of bound IgGs thus remains free to function as a ligand directed 
against a specific cell surface receptor (Ried et al. 2002). in vitro results show that the tropism 
of AAV vectors could be expanded to non-permissive cell types by inserting a 14-amino-acid 
peptide, L14 (QAGTFALRGDNPQG), at position 587 of the AAV2 capsid protein (Girod et 
al. 1999). In a different approach, single or multiple amino acid residues on the surface of the 
capsid were substituted or deleted and the resulting phenotype was characterized. Mutation of 
two crucial arginines led to the disruption of AAV binding to its primary receptor HSPG and 
therefore detargeting of a number of cell types; other substitutions caused increased resistance 
against neutralizing serum (Opie et al. 2003; Lochrie et al. 2006). Combination of this 
detargeting and retargeting strategies were combined to create mutants with new tropism. 
AAV mutants with inserted RGD-4C peptide at positions 520 and 584 showed loss of 
Heparin-binding and altered tropism (Shi et al. 2006). 
As an additional possibility, capsid proteins of different serotypes were mixed, leading to the 
formation of chimeric capsids with altered phenotype (Gigout et al. 2005; Wu et al. 2006).  
A general drawback of rational design approaches is the unpredictable change of the nature of 
insertions after integration into the capsid. To build up a viable capsid, the VP protein 
structure has to fulfill numerous specifications; educated guesses in mutagenesis of the viral 
shell often leads to non-functional VP protein. Insertions tend to not function in the originally 
expected way, because the course of capsid assembly and interactions between essential 
structure domains are not well-enough understood. 
3.4.2 Evolutionary approaches 
Controversy to rational approaches, evolutionary techniques create a very large number of 
randomly mutagenised variants of a biomolecule and thereafter screen this “library” for 
beneficial mutations without trying to predict the specific changes needed for the desired 
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phenotype. The general advantage of this technique is that it does not require detailed 
understanding of relationship between protein structure and function. On the other hand, 
generated libraries must be complex enough to include beneficial mutants and screening 
methods must be stringent enough to identify the latter ones. 
Evolutionary techniques have proven to be useful for protein optimization before being 
applied to viruses (Stemmer 1994; Vasserot et al. 2003). Directed evolution approaches for 
viral vectors are based on a general principle: the capsid surface is mutated randomly and 
large libraries of variants are generated. In this way, viral libraries are constructed carrying 
mutants with properties differing from those of naturally occurring serotypes or variants. The 
number of all serotypes and variants known until now, taken together is exceeded more than 
thousand-fold by the produced number of variants in one such library. Out of this large pool 
of mutants, beneficial variants can be selected using high-throughput screening methods even 
if specific knowledge of capsid biology is limited. Packaging-, infection- and replicative-
defective or -poor mutants can easily be ruled out during selections and mutants with 
beneficial phenotype for the desired application can be selected in clonal purity. Different 
techniques that have been previously applied in the field of AAV vectors are shortly 
introduced in this paragraph.  
Selection of novel peptides from phage libraries and subsequent insertion into AAV: 
tissue specific targeting peptides are identified by screening phage display libraries and 
subsequently inserted genetically in the capsid of AAV vectors (Nicklin et al. 2001; Work et 
al. 2005). Enhanced transduction of vascular endothelia cells was observed after insertion of a 
7mer SIGYPLP peptide at position 587 (Nicklin et al. 2001). Grifman et al. have incorporated 
a tumor-targeting peptide previously identified from phage display into rAAV2, which 
successfully shifted vector tropism (Grifman et al. 2001). However, as for rational design 
insertions, peptides identified in different viral contexts often lose or abate biological function 
once inserted in the architectural context of AAV particles. Moreover, AAV virions can lose 
stability or functionality as consequence of the peptide insertion (Kwon and Schaffer 2008).  
Insertion libraries: In this approach, randomized peptides are introduced at specific AAV 
capsid sites that have been previously proven to tolerate insertions in rational design studies 
(Girod et al. 1999). Site 587 was used by Perabo et al. to insert a random peptide library and 
select mutants with up to 100-fold infectivity on M-07e, a human megakaryocytic and a B-
cell chronic lymphocytic leukemia cell line (Perabo et al. 2003). Human coronary artery 
endothelial cells were targeted in an analougous approach (Muller et al. 2003). These 
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insertion libraries can also be panned to select mutants with immune escaping phenotype 
(Muller et al. 2003; Perabo et al. 2003; Maheshri et al. 2006; Perabo et al. 2006). In these 
insertion library approaches, the selected peptides are optimized for functioning in the 
architectural environment of the AAV capsid. 
Random mutagenesis libraries: Long stretches of the viral capsid can be randomly 
mutagenised, e.g. by error-prone PCR in order to introduce random point mutations. Point 
mutations were spread all over the viral capsid and immune escaping mutants were isolated 
out of such libraries (Perabo et al. 2006). These libraries also can be used to select mutants 
with altered receptor binding, tropism and transduction efficiency (Maheshri et al. 2006). 
Recently, such a library has been used for in vivo selection for tumor and lung targeting 
mutants (Michelfelder et al. 2009).  
Shuffling libraries: Natural biodiversity among AAV serotypes can be exploited by applying 
shuffling protocols, to swap capsid domains between serotypes via homologous 
recombination and to generate chimeric capsids. This procedure was used to generate mutants 
with mixed or novel phenotypes. AAV2 and AAV3 capsids were shuffled together and 
subjected to a Marker rescue assay, which reports the restoration of gene function by 
replacement of a defective gene with a normal one by recombination, resulting in chimeric 
particles with new characteristics such as altered receptor binding and infectivity (Bowles et 
al. 2003; Hauck et al. 2003). Hauck and colleagues combined capsids of AAV1 and AAV2, 
obtaining a library they were able to isolate mutants with combined beneficial features of both 
serotypes out of. A clone containing capsid fragments of serotypes 1, 2, 8 and 9 was isolated 
from an integrin minus hamster melanoma cell line previously shown to have low 
permissiveness to AAV. The mutant showed increased transduction rates on this celline and 
decreased antibody recognition compared to wild type serotypes (Li et al. 2008).  
All combinatorial methods can be transferred to other serotypes and vectors, enhancing their 
phenotypes for the desired purposes.   
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4 Results I 
4.1 Aiming for selectivity 
Application of viral vectors with wide and unspecific tropism in clinical applications may 
translate in dispersion of vector particles in non-target tissue and unleash side effects in 
unspecifically transduced organs. AAV2-derived vectors that carry suicide genes as 
transgenes for example can be used in anti cancer therapies only if they specifically target 
malignant tissue. Combinatorial techniques have already been used for selection of AAV2 
capsid mutants targeting refractory cells (Perabo et al. 2003; Yang et al. 2009). Despite 
showing high transduction rates however, these mutants lacked target selectivity and no 
protocol for isolation of cell type-specific mutants has been described yet. For technical 
reasons, it is easier to broaden vector tropism instead of restricting it for more specificity 
(Buning et al. 2008; Perabo et al. 2008; Michelfelder 2009). Recently, in vivo selection 
protocols have yielded clones with increased selectivity by sceening AAV libraries in mice 
(Arap et al. 2002; Grimm et al. 2008; Yang et al. 2009) or phage display libraries and 
eventually incorporating selected peptides in AAV capsids (Work et al. 2006). Since in vivo 
selections in human are ethically not feasible, I aimed to develop a straight forward in vitro 
protocol for the isolation of target cell specific AAV2 mutants. To achieve this goal, I tested 
the possibility to subject the viral library to positive and negative selection rounds in order to 
identify clones that efficiently infect a cell type used in the positive selection and inefficiently 
the cell type used in the negative selection step. 
 
4.1.1 Design of a directed evolution protocol and a viral insertion library 
The selection protocol for the isolation of specific mutants from a viral library consists of two 
steps. In the first step the library is incubated with non-target cells to deplete from the pool 
mutants that binding to these cells (negative selection). Eventually, the supernatant is 
transferred to target cells for 48 h. In this second step, the remaining virions can infect the 
cells and replicate (positive selection). After this step the viral progeny is harvested lysating 
the infected cells. Repeating this procedure several times, the initial pool is progressively 
enriched with mutants that do not efficiently bind to non-target cells but efficiently infect and 
replicate in target cells. After several selection rounds, the biodiversity of the pool is reduced 
to a level that allows identification of predominant clones (Figure 5).  
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Figure 5: Scheme of the selection protocol. The viral insertion library is produced in HEK 
293 cells. To select BLM specific mutants, the library is incubated with non-target cells 
(fibroblasts) before the supernatant is used for the infection of target cells (BLM). 48 h post 
infection, viral progeny is collected, analyzed and eventually introduced to the next selection 
round.  
 
As a target cell I used BLM, a human melanoma cell line which is highly permissive for 
wtAAV2. For the establishment of the protocol I decided for a cell line because homogeneous 
cell populations and large amounts of material were needed. The use of primary melanoma 
material might have led to problems in homogeneity of samples and sufficient material 
supply.  
To get rid of mutants that unspecifically infect BLM, a negative selection protocol was 
needed. I tested fibroblasts and keratinocytes for their ability to trap AAV particles. These 
cells naturally coexist with melanocytes in the same microenvironment in the body. 
The viral library used in this project was obtained by genetic insertion of 7 random amino 
acids on a peak of the viral capsid protein at amino acid position 587 (VP1-numbering) 
(Perabo et al. 2003) (see Figure 6). Since being present on all sixty VP proteins that build up 
the capsid, also the insertion is present sixty times on each capsid.The pool contains 
approximately 4x106 different clones, expressing each a different type of peptide at the 
insertion position. Since this position hosts the major receptor-binding site of the AAV2 
capsid (Xie et al. 2002), and since it is well exposed on the surface of the viral particle, 
mutants carrying a 7-mere peptide inserted at this site, depending on the particular peptide 
should have an altered tropism compared to wtAAV2.  
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Figure 6A: 3D structure of the VP3 capsid protein (Xie et al. 2002). The 587 site is indicated 
by the arrow. B: 3D structure of the AAV2 capsid , some of the 587 sites are indicated by 
yellow circles. 
 
4.1.2 Titration of adenovirus 
AAV belongs to the dependovirus family, a group of viruses that need the expression of 
helper genes in the host cell for replication. Among the proteins that can provide this function, 
gene products of adenovirus are potent effectors and adenovirus has been the helper agent of 
choice in all AAV library screening procedure described so far. The amount of adenovirus to 
be used in each different selection procedure requires exact dosage. If the load of adenovirus 
is to low, the helper effect provided is sub-optimal and AAV replication will be reduced. Too 
much adenovirus causes cytolysis and therefore reduces the production of AAV particles. The 
optimal amount of adenovirus to support AAV replication in BLM cells was identified in a 
single titration experiment (Figure 7). HeLa cells were infected with 103 wtAAV2 particles 
per cell and increasing amounts of adenovirus. The total viral progeny was measured after 48 
h by quantitative PCR (qPCR). The progeny titer increased proportionally to the amount of 
adenovirus from 0-1400 pfu/cell and reached the highest level (3.6x1010 genomic particles) 
when an adenovirus titer of 2800 pfu/cell was used. Beyond this concentration the production 
of AAV particles decreased (1.1x1010 genomic particles at 5600 pfu/cell). The MOI of 2800 
pfu/cell was used for the below described selection protocols. 
Results I 
22 
 
 
Figure 7: Determination of the optimal adenovirus concentration for the replication of AAV 
in BLM cells. Cells were coinfected with same amounts of wtAAV2 and increasing amounts of 
adenovirus (plaque forming units per cell pfu/cell). AAV progeny was measured by qPCR 48 h 
post infection (single experiment). 
 
4.1.3 Adjusting selective pressure  
To optimize the selection pressure needed for the negative selection, the decoy ability of 
primary human fibroblasts and primary human keratinocytes was tested. Fibroblasts 
effectively depleted viral progeny during the negative selection step. After the following 
positive selection step the relative viral progeny was more than 100x (6.6x103) lower as 
compared to no negative selection (1.5x106) or negative selection on keratinocytes (1.2x106) 
(Figure 8). The reason that prevented keratinocytes to deplete the viral pool was not further 
investigated. For the successive screening experiments we used exclusively human primary 
fibroblasts as cellular decoys. 
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Figure 8: Decoy ability of keratinocytes and fibroblasts.  Same amounts of display library 
were incubated in 6-wells containing no cells, keratinocytes or fibroblasts. After two hours, 
the virus-containing medium was transferred to BLM cells. The viral progeny produced of BLM 
cells was measured by qPCR 48 h post infection. 
 
A crucial parameter for the success of this kind of selection procedures is the amount of 
AAV-library to be used. If the initial amount of virions is too low, biodiversity will be poor 
and the chance of the pool to contain interesting mutants decreases. Conversely, using too 
many virions per cell could lead to multiple infections of a single cell, resulting in the 
formation of chimeric particles and therefore in the uncoupling of genotype from phenotype 
in the viral progeny produced in these cells. The chimeric mutants that are produced in this 
case would impair the selection process. In addition, the negative selection capacity of 
cultured cells is limited: cells can only bind a finite number of virions, before surface 
receptors are oversaturated. 
In order to determine the range in which the decoy effect of fibroblasts is effective, I 
measured the total viral progeny after a test-selection round (consisting of a negative 
successive a positive selection) either with or without the negative selection step, using 
different initial amounts of genomic particles (Figure 9).  
Increasing the initial amount of AAV from 102 to 104 genomic particles per cell (GOI) 
resulted in increasing total viral outcome if no negative selection was carried out. In contrast, 
viral progeny after negative selection on fibroblasts was efficiently decoyed even when the 
highest amount of virus was applied. Input of more viral particles increases biodiversity and 
therefore the chance of the pool to contain interesting clones. Although the negative selection 
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potential was not yet saturated, no higher amounts of initial virus load were tested in order to 
avoid formation of chimeric particles that form at multiple infection of the same cell by 
different insertion mutants. The resulting uncoupling of genotype from phenotype impairs the 
selection process. 
 
 
Figure 9: Decoy effect of Fibroblasts cells at different GOIs.  The viral library was amplified 
on BLM cells without (black bars) or with (grey bars) negative selection on human primary 
fibroblasts. Relative progeny titers were measured by quantitative PCR 48 h post infection. 
 
4.2 Selection of BLM specific mutants 
To compare the effect of using different initial amounts of viral particles, two selection 
procedures were performed in parallel.  
In one setting, a low number of particles (GOI = 100) was applied and three consecutive 
selection rounds were performed. Sequencing of the viral pools showed that one mutant G2 
(carrying the insertion RSGQSLS) dominated the pool already after the first selection round 
accounting for more than 50% of the total number of clones. This mutant persisted in the 
following selection rounds. When tested in an infection assay it showed no increased 
specificity compared to wtAAV2 (see Table 1). This experiment suggested that the selection 
pressure had depleted the low biodiversity of the pool too sharply. In this conditions 
apparently, the evolution of the pool had the characteristics of a genetic drift instead that of a 
real selection, in which stochastic events led to the surviving of a mutant that showed no 
selective advantage. 
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In the second setting, four consecutive selection rounds (each consisting of a negative 
successive a positive selection) were performed using a GOI of 104. Evolution of the pools 
was monitored  by qPCR and sequencing. Twelve clones of the first round´s progeny pool 
were sequenced to avoid preceding a selection with a pool in which one clone has already 
ruled out the others (as described above). All sequences appeared only once, suggesting that 
biodiversity was still high. The pool was amplified on BLM cells to cover the titer needed for 
the next cycle. 
After the second selection round, sequencing of the pool showed that biodiversity was 
reduced. 12.5% of 24 sequences were represented by three mutants. Titers of the progeny for 
both initial GOIs were in a range of one log and had again more than doubled (3.2-fold; 2.1-
fold), compared to the preceding selection round, indicating the increasing overall fitness of 
the pool. 
 
Figure 10:  Selection procedure monitored by qPCR.  
 
In order to analyze the pools for accumulated clones a total of 98 samples of all viral pools 
was sequenced. No redundant clone was found after the first selection round. The insertions 
found here did also not reappear in the sequences of later selection rounds suggesting that the 
biodiversity of the pool was still high. 
In contrast to this, sequencing of at least 20 clones from each of the later selection rounds 
showed a gradual decrease in biodiversity and the appearance of clones in multiple copies. 
The redundancy of clones in the sequenced pools was 0% after the first round, 12.5% after the 
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second, 33% after round three and 66.7% after selection round 4. The observed increase in 
viral titers (despite the lower initial amounts of viral particles used in the last two selection 
rounds), and the concomitant decrease of biodiversity are strong indicators of a successful 
pressure-driven selection. 
45% of the sequenced viral pool after the fourth selection round was composed of five clones 
(A7, C4, D8, D10, E10) that were packaged with GFP to further analyze their characteristics. 
 
4.3 Characterization of selected mutants 
4.3.1 Packaging capacity of selected clones 
GFP-expressing vectors carrying the selected 587 capsid insertions were produced and 
analyzed for their specificity as described in materials and methods. An additional clone that 
was only found once in the pool after the fourth selection round (A5) was also characterized 
as an example of a mutant that was not strongly selected (see Table 1). Titers were measured 
via qPCR showing that mutants A5, C4, D10 and E10 packaged with efficiencies comparable 
to wtAAV2. Conversely, A7 and D8 viral preparations yielded genomic titers 103- and 211-
fold lower than wtAAV2, respectively. This observation could be confirmed after repeating 
the viral packaging procedure in two additional experiments. Since these low titers allowed 
performance of infections only at GOIs that failed to yield detectable transduction rates on 
BLM cells (data not shown), mutants A7 and D8 were not further characterized. The low titer 
yield of these mutants can be due to ineffective packaging of the transgene or some other 
difference between selection and packaging that is disadvantageous for the packaging 
efficiency of A7 and D8. Mutants A5, C4, D10 and E10 were subjected to further 
characterization.   
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vector 
 
amino acid sequence of 
insertion 
% of sequenced 
clones observed in selection 
round: 
genomic particles/µl 
 
wt -   (2.10 ± 0.26) x 108 
G2* RSGQSLS - 1 (1.91 ± 0.45) x 108 
A5** DAANNPR 1x 4  (8.71 ± 1.51) x 107 
A7 NDPRKPS 10.5 2, 3, 4  (2.04 ± 0.15) x 106 
C4 PRGTNGP 5.8 2, 3, 4  (1.27 ± 0.26) x 108 
D8 AGKAGIG 15.1 3, 4 (9.93 ± 1.12) x 105 
D10 SRGATTT 8.1 2, 3, 4  (1.67 ± 0.18) x 108 
E10 DGSGPTR 5.8 2, 3, 4 (8.88 ± 2.64) x 107 
 
 
 
Table 1: Characterization of selected mutants. Titers were calculated as mean of 3 
independent measurements.(*:G2 mutant was selected after using an initial GOI of 100;**: A5 
mutant was only observed once in the last selection round) 
 
4.3.2 Selectivity assay 
To estimate the selectivity of the mutans, target and non-target cells were infected with GFP-
vectors. GFP is expressed only in the infected cells so that the percentage of transduced cells 
can be distinguished from non-infected ones by cytofluorimetry 48 h post infection (see 
Figure 11 A-E). To exclude that results were influenced by the particular amount of genomic 
particles per cell used in the experiment, triplicate experiments were performed at six 
different GOIs. For quantification of target cell specificity ratio, three GOIs were chosen that 
fulfilled the following requirements: more than 25% and less than 75% of BLM cells and 
more than 3% of fibroblasts had to be infected by the given GOI (marked in Figure 11 A-E by 
caskets). It turned out that the values of infectivity ratios in the GOI range identified by these 
parameters were similar (Figure 12) and the final ratio of infected BLM and fibroblast cells 
was calculated as mean of these three values for each mutant (Figure 11 F). 
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Figure 11: A-E:  Transduction efficiencies of wtAAV2 and selected mutants on BLM cells 
(black) and human primary fibroblasts (white). Infections were performed with six different 
multiplicities of infection (x-axis). Transduction rates were calculated as percentage of 
fluorescent cells. Values are given as average of three independent infection experiments, 
error bars represent standard deviation . The ratios marked in the caskets were used to 
quantify specificity ratios of each mutant (F).  
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Figure 12 Ratios for all tested mutants of infectivity of BLM and fibroblast cells at three 
different GOIs that were used to quantify specificity. 
 
The mutants´ infectivity ratios were 1.8, 1.8, 2.8, 5.7 and 6.6 for wtAAV2, mutants A5, E10, 
C4 and D10, respectively (Figure 12 F). Specificity of the mutants was calculated comparing 
mutants´ratios with those of wtAAV. The respective values are 1.0, 1.6, 3.2 and 3.7 times 
higher for A5, E10, C4 and D10 (Figure 13).  
 
 
Figure 13:  Selectivity of mutants on BLM cells and fibroblasts. Infection ratios were 
quantified for wt and mutants and related to specificity of wtAAV2. 
 
These results indicate that a lower unwanted transduction of non-target cells occurs when 
using the mutants. This outcome is depicted in Figure 14 comparing directly the curves of 
D10 and wtAAV infection demonstrating that a virus dose that infects 54% of BLM cells 
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would collaterally infect 30% fibroblasts when using wtAAV2 but only 8% when using D10 
mutant. 
 
Figure 14: Comparison of transduction efficiencies between wtAAV2 (black) and mutant D10 
(white) on BLM cells (circles) and human primary fibroblasts (triangles) with increasing 
amounts of virus. 
 
4.3.3 Selected mutants are inhibited by heparin 
To further characterize the mutants, their ability to interact with AAV2 primary receptor, 
heparan sulfate proteoglycan (HSPG) was tested. Heparin is the sugar content of HSPG and 
the soluble form of this molecule can bind to the viral capsid of wt AAV2 suppressing its 
ability to bind HSPG on the cellular surface in a competitive way. Since the randomized 
peptides are inserted in the HSPG-binding region of the capsid, depending on the amino acid 
composition of the peptide, the HSPG binding phenotype of the virions could be altered with 
important consequences for the tropism of the viral particles (Perabo et al. 2006).  
To assess the ability of the selected clones to bind HSPG, GFP-vectors derived from wtAAV2 
and from insertion mutants were incubated for 30 min with HeLa cells at a concentration of 
6x103 genomic particles per cell in the presence or absence of 85 I.E./ml heparin. 48 h later, 
the percentage of infected cells was analyzed by cytofluorimetry (Figure 15). All mutants 
were inhibited by heparin. wtAAV2 and A5 mutant were almost completely blocked (3.1%; 
3.5% residual infectivity) whilst E10, C4 and D10 showed higher residual infection rates 
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(22.5%; 9.3% and 17.2%). The fact that mutants selected after four rounds are not inhibited 
by soluble heparin as efficiently as wtAAV2 and A5 suggests a reduced binding of these 
mutants to HSPG, which in turn could explain their reduced infectivity on fibroblasts and 
other cell types. Retention of BLM tropism could be explained by their ability to use the 
selected insertion peptide to  bind alternative receptors.  
 
Figure 15: Transduction efficiencies of wtAAV2 and selected mutants in the presence (black 
bars) or absence (white bars) of soluble heparin.  The percentage of infected cells was 
quantified 48 h post infection via cytofluorimetry. 
 
4.3.4 Tropism for other cell types 
In order to estimate the specificity of selected mutants with regard to other cell types (not 
used in the negative selection step), infection assays were conducted on primary 
keratinocytes, three primary melanoma cell cultures obtained from different patients, a breast 
cancer cell line and  a murine embryonic fibroblast cell line (Figure 16). The BLM-specificity 
of the mutants was similar on primary fibroblasts (F), primary keratinocytes (K) and primary 
melanoma samples (M1-3), although some variation was observed. In particular, E10 reached 
3-fold increase of BLM selectivity vs. M1 cells. C4 had higher selectivity values than D10 on  
murine fibroblasts (MF, showing a ratio of 2,8) keratinocytes (K, showing a ratio of 4.5) and 
breast cancer (B, showing a ration of 6,4, which compared to the 1.4 ratio of D10). 
These data show that the BLM-selectivity of the selected mutants is not restricted to the cell 
type used in the negative selection but appears to regard a wide spectrum of other cell types as 
well. 
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Figure 16: BLM selectivity of capsid mutants in comparison with human primary fibroblasts 
(F), human primary keratinocytes (K), human primary melanoma cells obtained from three 
different patients (M1-M3), human breast cancer cells (B) and murine fibroblast cells (MF).
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5 Discussion I (Specificity selections) 
 
One of the major problems for safe and efficient AAV-based gene therapy is the lack of 
tissue-specific targeting vectors. Although effective targeting to AAV non-permissive cells 
has been achieved by insertion of appropriated ligands in the wt capsid or direct selection 
from insertional targeting libraries (Girod et al. 1999; Muller et al. 2003; Perabo et al. 
2003), these methods mostly generated vectors with extended tropism that however, lacked 
selectivity. This was due to targeting of widely expressed receptors and because of the 
existence of important receptor binding domains on the capsid, which remain functional 
despite the insertions. 
I developed in this work an in vitro selection procedure that includes positive and negative 
selection steps for the first time. Applying the new selection protocol to an insertion library 
that was used to identify mutants with altered tropism but no specificity gain before 
allowed isolation of AAV2 insertion mutants with up to 3.7-fold increased specificity for 
the target cells.  
Two of the selected clones (A7; D8) were recovered most frequently after the selection 
process but could not be produced with sufficient titers as GFP-expressing vectors 
although iterating three times the packaging procedure. The reason for this was not further 
investigated. One possibility is that the transgene used in my experiments (GFP) is not 
efficiently packing into these mutants. Another possibility is that these clones have a 
phenotype that confers a selective advantage during selections but is disadvantageous 
during the packaging procedure. It was reported before that capsid insertion mutants were 
not efficiently packaging (Yang et al. 1998). In future trials, mutants with these phenotypes 
could be ruled out by interposing a packaging step during selections. 
Three mutants that were strongly selected (E10; C4 and D10) showed increased selectivity 
of 1.6, 3.2 and 3.7 times compared to the wildtype for BLM cells that were used for 
positive selections compared to fibroblast which served as decoys for the negative 
selections. Selectivity was not due to higher infectivity on target cells but rather to 
decreased transduction efficiency on non-target cells. A likely explanation of the observed 
tropism characteristics of the mutants is a reduction of their ability to bind to widely 
expressed membrane receptors caused by the peptide insertion. Instead, the inserted 
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peptide could confer the ability to recognize and bind a different receptor that is 
specifically expressed by BLM cells. Although the differences between wildtype and 
mutant tropism are not understood on the molecular level, this demonstrates that thanks to 
the negative selection step, the selection pressure applied in the overall screening 
procedure was driving the isolation of selective mutants and not of clones that are 
unspecific but very infectious.  
Interestingly, although negative selection rounds were performed exclusively on human 
primary fibroblasts, primary melanoma cells from three patients and keratinocytes were 
also infected less efficiently by the three selected mutants than by wtAAV2. This result 
suggests that the change in viral tropism was exactly targeted towards BLM cells and not 
generically to melanoma cells. Selected virions interact with surface receptors that are 
expressed exclusively or more abundant on BLM. Although membrane receptor expression 
profiles of the tested primary melanoma samples were not analyzed, it is known that they 
differ between individual cases (Sekulic et al. 2008); so it is likely that differences in 
membrane receptors composition between BLM and primary cells accounted for the BLM-
specificity of the selected mutants. A partial exception was mutant C4 which infected 
patient melanoma cells (M1) almost as efficient as BLM cells, suggesting that this capsid 
variant is able to recognize one or more receptors present on both cell types. 
The results demonstrate the potential of combinatorial techniques to isolate cell type 
specific capsid mutants from viral insertion libraries and provide the first proof of principle 
that negative selection is a suited method to restrict viral tropism to a defined cell type, 
reducing collateral infection of other cell types.  
Interestingly, the two most specific mutants identified in these experiments carry very 
different peptide insertions (C4: SRGATTT; D10: PRGTNGP) and accordingly show 
different tropisms. C4 for example, is less BLM-selective than D10 when compared on 
fibroblasts and primary melanoma cells but it is more selective on keratinocytes, breast 
cancer cells and murine fibroblasts compared to BLM. This suggests that the biodiversity 
present in the library and the described selection method can yield mutants that carrying 
different insertion, achieve the goal of increased specificity by targeting distinct receptors, 
although molecular mechanisms have to be resolved to proof that.  
During the selection process, insertion peptides with similar sequences have accumulated 
leading to different variants that share analog properties. Remarkably, all 98 sequenced 
Discussion I 
35 
 
mutants (including those from the original library) carry at least one positively charged 
amino acid in the insertion peptide and all of the selected mutants carry an arginine; C4 
and D10, the most specific ones carry an overall positively charged XRGXXXX peptide. A 
positive charge seems to be essential for the virions to survive the selection procedure. The 
pattern of peptides showed no commonly known binding motive, but the XRGXXXX 
motive could mimic a binding motif of wtAAV2, that also carries an RG motif at position 
585-586. This could on one hand preserve the tropism necessary to still successfully infect 
BLM cells, and on the other hand introduce enough architectural modifications to decrease 
affinity for receptors that allow infection of fibroblasts. Interestingly, this RG motif could 
be part of an unknown integrin binding motif. RGD peptides are well known binding 
motives for cellular integrins which are especially involved in the oncogenic 
transformation on many cancer cells (Eble and Haier 2006). Noteworthy in this respect, 
RGD motives were selected in previously described panning procedure of the same library 
used here (Perabo et al. 2003). Exploiting the full potential of peptide variability, directed 
evolution strategies might allow finding new binding motives that are either unknown or 
do not exist in nature. 
The A5 mutant was not significantly differing in phenotype from the wt virus, showing 
that unspecific mutants remained in the pool even after four selection rounds. The insertion 
of A5 seems to be neutral for the tested phenotypic characteristics, showing that it is 
important to optimize the selection protocol in order to enable clones with beneficial 
phenotype to prevail against neutral clones. To reach this aim, viral pools could be 
passaged multiple times over non-target cells before proceeding to the next selection step. 
This technique could also be used to apply more complex negative selection pressure and 
even more specific selection by using multiple distinct non-target cells. Otherwise, the 
results show that the mutants tropism was restricted specifically to BLM and they were not 
efficiently infecting primary melanoma samples. This is also a hint that therapy vectors e.g. 
for melanoma had to be selected for each individual case of disease since the cell surface 
characteristics e.g. on melanoma samples can be different from case to case (Sekulic et al. 
2008).  
Since selected mutants maintained their heparin binding abilities and since secondary 
receptor binding domains of the capsid might be located apart from the library insertion 
site, the pool screened in these experiments might have been biased with mutants that 
mostly retain their natural tropism, limiting the potential for discovery of selective clones. 
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Combining the insertion of randomized peptides with mutations aimed at disrupting natural 
receptor binding domains could push the selection towards the isolation of more selective 
mutants that use alternative cell entry routes.  
The here described mutants were selected an tested in an in vitro system and have not been 
tested in vivo. In the future selected mutants will be tested in a BLM mouse model. This 
will allow the characterization of selectivity in a situation where the mutants are 
challenged by a higher number of different cell types at the same time, but with the 
addition that this model system is not directly transferrable to human. Recently, in vivo 
selections in mice have been applied using a peptide insertion library. However, selected 
mutants were not specific (Michelfelder et al. 2009). The results of in vivo selections in 
mice can not automatically be transferred to the human system. Since humans are AAV2´s 
natural host, animal models  
Since different cell types could be targeted by similar methods and the protocol can be 
adapted to other viral platforms, these results open new perspectives for the engineering of 
patient- and cell-specific gene therapy vectors. However, to engineer a selective vector 
suitable for in vivo application, detargeting and targeting strategies can be combined. The 
mutation of more than one site might be required to generate a mutant with all desired 
characteristics. 
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6 Results II 
6.1 Aiming for antibody evasion 
A major issue in the development of viral vectors for human gene therapy concerns the 
host´s immune response to the virus. AAV2 derived vectors do not trigger severe immune 
responses in humans (Warrington and Herzog 2006). Recent surveys however have shown 
that cellular immune response mechanisms can induce mild liver inflammation and lead to 
shut off transgene expression (Manno et al. 2006). Additionally, depending on ethnic 
group and age up to 80% of individuals have been naturally infected by AAV2 and carry 
antibodies that can neutralize virus or vector particles, reducing or completely abolishing 
the therapeutic efficacy of gene transfer (Calcedo et al. 2009).  
For chronic diseases and long-time treatment, immunologic reactions can be suppressed 
efficiently for every consecutive treatment (Manning et al. 1998). This treatment however 
is cumbersome, uncomfortable and risky for the patient. An alternative to immune 
suppression of the patient during treatment is the use of vectors that are not recognized by 
pre-existing antibodies. The discovery of a large number of natural AAV variants has 
provided a large spectrum of capsid alternatives that can be employed to circumvent 
neutralization by the immune system. However, due to marked differences in capsid 
composition, these serotypes substantially differ from AAV2 tropism, and are often not 
suited for use in therapeutic application requiring AAV2 like tropism and infectivity rates. 
Furthermore, patients treated with this alternative serotypes would likely produce 
neutralizing antibodies after the first application (Halbert et al. 2000).  
For these reasons, immune escaping vectors are of great interest for clinical application 
since they could supersede immunosupression and offer the possibility to treat patients 
with lower vector doses. An attractive idea is to engineer novel variants that escape 
neutralization from pre-existing antibodies but maintain the desired tropism. Even if these 
variants would also trigger the production of neutralizing antibody after their application, 
the availability of a pool of ad hoc engineered immune-escaping capsid alternatives would 
provide the possibility to successfully administrate therapeutic vectors for consecutive 
treatments. 
Genetic engineering by rational design or directed evolution has been recently used to 
generate capsids that escape antibody neutralization and has led to identify several amino 
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acid residues of the capsid proteins that can be mutated in order to decrease antibody 
recognition. Despite providing an important proof of principle however, near-to-
physiological range concentrations of antibodies could still neutralize transduction of these 
vectors (Lochrie et al. 2006; Maheshri et al. 2006; Perabo et al. 2006; Perabo et al. 2006).  
 
 
Figure 17 A: Described positions of capsid mutations that yield in an immune escape 
phenotype (red). White circles mark the clustering of beneficial mutations around the three-
fold symmetry spike of the viral capsid. B: Positions chosen for the pdegen5Lib library. 
 
To optimize the protocol, all relevant data published to date was analyzed. These data can 
be summarized in Figure 17 A, depicting approximately 20 positions which - if mutated 
yield in immune-escaping capsid variants. The positions cluster on the 3-fold symmetry 
spikes of the AAV2 capsid. All trials conducted so far used labor-intensive cloning 
strategies, educated guesses or combinatorial techniques in which large capsid regions 
were mutated randomly. We hypothesized that the limitations of former trials was mainly 
due to two reasons. First, a complete immune-escaping phenotype requires combination of 
more antigenic domains concomitantly. Combinatorial libraries screened in these studies 
have been obtained by capsid randomization by error prone PCR. Since amino acid 
substitutions are likely to generate defective particles, the mutation rate has to be kept 
relatively low at each selection round to avoid excessive modification of the capsid 
topology. This results in a slow, progressive selection of mutations that requires multiple 
re-iterations in order to combine beneficial mutations. Even if DNA shuffling has been 
used in the study of (Perabo et al. 2006) to accelerate accumulation of mutations, it is 
possible that the selection rounds were stopped before optimal mutants had been generated. 
Another possibility is that the amino acids used to substitute the original residues at the 
antigenic sites were not the most appropriate to confer a stealth phenotype. The effect of 
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the kind of amino acids substitutions of selected immune escape variants on the phenotype 
was never further analyzed. However, since various amino acids have different chemical 
and structural properties, also their effect on a crystal-like structure like the viral capsid 
protein should differ. My working hypothesis was that substitutions of similar amino acids 
on unimportant sites show no or low phenotypic effect compared to exchanges at positions 
relevant for antibody recognition and substitution with more distinct amino acids. In an 
ideal approach, all beneficial positions described in former trials should be substituted. 
However, a complete randomization of twenty amino acids would require the availability 
of a library with 2020 different clones, which is technically impossible to obtain.  Currently, 
technical limitations allow the production of combinatorial libraries of AAV capsids 
containing approximately 108 different clones. Therefore, only one or two amino acids 
would be represented at each position after randomizing 20 positions.  
With this in mind, I restricted mutagenesis to five positions previously described as being 
important for antibody recognition (see Figure 17 B). Through reduction of randomized 
positions from twenty to five I decreased the number of possible variants from 2020 to 205 
(3,2x106).  
 
6.1.1 Generation a complete randomization library (pdegen5Lib) 
A library of the AAV2 capsid mutants was generated, randomizing amino acid positions 
449, 458, 459, 493 and 551 (VP1-numbering) by PCR using primers containing the NNS 
codon that gives rise to all 20 amino acid residues and minimizes the frequency of stop 
codons for randomization of triplets in each position. After cloning, randomization was 
verified by analyzing the sequencing profile of the obtained pool (see Figure 18) and by 
sequencing of 41 clones (see Figure 21). No redundant mutant or a strong bias towards 
predominant amino acids was observed. A statistical evaluation of the diversity of the pool 
allowed quantifying that the obtained library consisted of approximately 6x106 variants 
and therefore statistically represents all possible combinations of amino acids at the chosen 
sites (see 10.2.6 for technical details).  
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Figure 18: Sequencing profile of the viral library (Chromas software). The randomized 
positions are indicated by red circles. 
 
6.2 Selection of immune escaping mutants 
To screen the library for immune escaping mutants I used a selection protocol that was 
previously described (Figure 19)(Perabo et al. 2006). Before infecting HeLa cells the viral 
library was incubated with neutralizing human serum that was obtained with informed 
consent from the Klinikum Großhadern in Munich and tested for the ability to neutralize 
AAV2 infection (Huttner et al. 2003). After two days, viral progeny was harvested and 
analyzed via qPCR and sequencing before being applied to additional selection rounds. 
The procedure favors the accumulation of mutants that despite the presence of neutralizing 
antibodies can infect the cells and replicate themselves - all valuable attributes for a gene-
therapy vector. 
6.2.1 Selection procedure 
Four consecutive selection rounds were performed starting with the pdegen5Lib library 
applying a total of 109 genomic particles (GOI = 100) in the first three rounds and 108 
genomic particles (GOI = 10) in the last selection round. To monitor selective pressure and 
antibody evasion phenotype of the pools at every selection round viral progeny titers were 
analyzed by qPCR. In addition, control selections were performed without serum and using 
wtAAV2 instead of the libraries in parallel. The pools that were exposed to the highest 
selective pressure in each round were used for subsequent rounds (see Table 2). 
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Figure 19: Scheme of the protocol used for immune escape selections. The viral library is 
incubated with neutralizing human antibodies before infection of HeLa cells. 48 h post 
infection, viral progeny is harvested, analyzed and eventually introduced to another 
selection round. 
 
In the absence of serum, or with serum concentration of 5%, progeny titers obtained from 
infection with wtAAV2 or with the pools were comparable in all selection rounds, 
indicating that no selective pressure was active and that wtAAV2 and library clones are 
similarly efficient in producing progeny on HeLa cells. In contrast, incubation with 33% 
serum led to a drop of 99.5% and 99.9% (compared to the titers obtained without serum) 
for the library and for wtAAV2 respectively. Therefore, 33% serum (and 0% as control) 
was used in the second selection round.  
In the second round the yield of total library pool progeny after incubation without serum 
was increased 6.8 fold. However, incubation with 33% serum diminished the progeny 
production by more than 99.99% (compared to the titers obtained without serum) for both 
wtAAV2 and pool progeny. Despite higher progeny loss, absolute pool progeny titers 
harvested were higher than after the first round.  
Hence, during the third round 50% serum was applied in parallel to using 33% serum in an 
additional experiment to apply even more stringent selective pressure. Wt was only treated 
with 0% and 33% serum and showed a decrease of progeny titer of 99.9% compared to 
only 90.8% of the pool. Selective pressure applied by 50% serum incubation reduced pool 
progeny titers by more than 99.9% but a progeny titer of (1.11 ± 0.18) x 107 could be 
recovered and was sufficient for the next selection round.  
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For the fourth selection round, GOI was reduced to 10 for the pool to increase the 
antibodies per virus ratio and therefore the selective pressure. Strikingly, despite the GOI 
reduction and the use of 50% serum, the yield of progeny was 71% of the total progeny 
recovered when the initial library was applied without serum and 142 fold higher than the 
progeny obtained after challenging the initial library with 33% serum, suggesting that the 
pool was evolving towards a population of viral clones with increased ability to infect cells 
despite the presence of AAV2 neutralizing antibodies.  
Another way to demonstrate evolution of the viral pool is to calculate the relative viral 
progeny of the pools and the wt in every selection round, since they were treated equally 
and the same GOI was applied (except for the fourth round). The results clearly indicate 
that the fitness of the library was increased during the selection rounds (see Figure 20). 
Relative progeny titer is constantly rising from 3.8-fold to 975.6-fold compared to wt. 
selection 
round 
 % serum 
progeny titer of 
pools/µl 
progeny titer of wt/µl 
Relative progeny 
pools/wt  
1 0 (1.68 ± 0.07) x 1010 (1.63 ± 0.08) x 1010 1.0 ± 0.09 
1 5 (1.12 ± 0.12) x 1010 (1.50 ± 0.07) x 1010 0.7 ± 0.12 
1 33 (8.43 ± 0.53) x 107 (2.20 ± 0.26) x 107 3.8 ± 0.69 
     
2 0 (1.15 ± 0.04) x 1011 (1.19 ± 0.16) x 1010 9.7 ± 1.61  
2 33 (1.58 ± 0.16) x 108 (8.01 ± 0.43) x 105 197.3 ± 30.4 
     
3 0 (1.85 ± 0.21) x 1011 (4.60 ± 0.30) x 1010 4.0 ±0.72 
3 33 (1.70 ± 0.10) x 1010 (5.90 ± 0.40) x 107 288.1 ±  36.7 
3 50 (1.11 ± 0.18) x 107 n.d. - 
     
4 50 
(1.20 ± 0.04) x 1010 
GOI = 10 
(1.23 ± 0.04) x 107      
GOI = 100 975.6 ±70.7 
 
Table 2: Selection monitoring. Serum concentrations, viral progeny titers of pools and wt, 
relative progeny (pools/wt) of all tested pools in all selection rounds. The pools in bold 
letters were applied to the next selection rounds and used for sequencing.  
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Figure 20: Comparison between viral progenies obtained from wtAAV2 and evolving pool 
during selection rounds. Values in the Y axis are expressed as ratio between progeny 
obtained from library infection and wtAAV2 infection. 
 
6.2.2 Selection results 
14 clones were sequenced after the 2nd round. No redundant clone was found and no bias 
for predominant amino acids observed, indicating that biodiversity was still too high to 
isolate predominant clones. Interestingly, only one charged amino acid (Asp) was found 
(mutant A11, position 551). 
43 clones of the progeny harvested after the fourth selection round were sequenced (see 
Figure 21). No predominant clone was observed and only one mutant appeared twice, 
which could be due to the cloning procedure and is not a result demonstrating adequate 
selection advantage of that single clone. However, the overall number of different amino 
acids found in the five randomized positions decreased substantially for all positions, 
suggesting that the biodiversity had been reduced by the selective pressure.  
Evaluation of the sequenced sample of the pool showed that small hydrophilic amino acids 
were positively selected at all five positions while the proportion of big, hydrophobic 
amino acids had all-over reduced (see Table 3). A possible explanation is the general 
advantage of small, hydrophilic amino acids to fulfill better the needs of the virus surface 
to be water-soluble and not disturb protein folding. Interestingly, no proline was found at 
positions 449, 459 and 551 and only a proportion of 5% at site 493 after selection. In 
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contrast, the proportion of proline was increased from 2% in the library to 19% in the 
selected pool at position 449 indicating a positive stabilizing or folding effect at this 
specific position. Alkaline amino acids were only found at positions 458, 459 and 551 after 
selection. Acidic amino acids were completely lost at positions 449, 458, 459 and 493 but 
the proportion was doubled at position 551. A beneficial immune escaping phenotype of 
negative amino acid at this site was reported before (Perabo et al. 2006). The results 
demonstrate the potential to narrow down the kinds of amino acids beneficial for capsid 
biology at specific sites without identification of a predominant clone and may help to 
better understand the structural requirements of each site on the virus surface. This can 
lead to a reduction of trial and error procedures in future approaches. 
Since a clear reduction of biodiversity was observed together with an overall enhanced 
phenotype of the pool after the fourth selection round 16 clones were picked and packaged 
with GFP to test their packaging capacity and immune escaping phenotype. 
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Library: 
 
Pool after 4th selection round: 
 
Figure 21: Sequences of the viral library before selection (upper panel) and the viral pool after the fourth 
selection round (lower panel). (Bioedit software; wt sequence on top) 
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Amino acid Position 449 Position 
458 
Position 459 Position 493 Position 
551 
wt amino acid N S R A N 
wt sequence observed (%) 12/7 22/9 7/7 24/28 22/37 
different amino acids 
observed  
16/7 15/10 17/9 15/7 13/8 
small, hydrophilic (%) 40/87(wt) 46/55 (wt) 42/65 32/62 70/74 
(wt) 
big, aromatic, hydrophobic 
(%) 
41/12 37/21 34/23 39/33 (wt) 15/9 
proline (%) 0/0 2/19 2/0 15/5 0/0 
alkaline (%) 12/0 12/5 15/12 (wt) 7/0 7/2 
acidic (%) 7/0 2/0 7/0 7/0 7/14 
Table 3: Number of different amino acids observed in total and percentage distribution in 
the library (n=41) and the selected pool (n= 43).  (Values were rounded to full numbers) 
 
 
6.3 Characterization of selected mutants 
6.3.1 Packaging of GFP- rAAV vectors 
Eight mutants, representing diverse chemical compositions of the mutations at the five 
randomized positions were chosen for further characterization. In addition, four clones of 
the unselected library and four of the pool after the second selection round were 
characterized to evaluate the influence of selection on virions phenotype.  
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Vector 
 
Amino Acids at positions 
449, 458, 459, 493 and 551 
Genomic titer/µl 
Capsid titer/µl 
Capsids/ genome 
 
wt NSRAN (1.90 ± 0.05) x 108 1.18 x 109 6,2 
AAV1 - (2.91 ± 0.17) x 107 n.d. - 
K4 NSKAD (2.05 ± 0.06) x 107 4,61 x 108 23 
B6 AGSLG (1.43 ± 0.06) x 107 n.d. - 
B8 TARSA (1.14 ± 0.10) x 107 1,60 x 108 14 
C4 CQCGK (5.55 ± 0.09) x 107 1,03 x 109 19 
C7 ICMDC (2.24 ± 0.05) x 106 n.d. - 
A2* ASCMG (4.63 ± 0.21) x 107 9,44 x 108 20 
A11* AYGGD (5.10 ± 0.40) x 107 8,18 x 109 16 
B2* AGGGQ (1.32 ± 0.08) x 108 1,01 x 109 8 
B10* AGTTG (5.74 ± 0.19) x 107 2,29 x 108 3,9 
C6** QQVSA (4.50 ± 0.35) x 108 1,74 x 109 4 
E3** TPQSD (1.15 ± 0.12) x 107 2,38 x 108 21 
E4** AYGTE (5.17 ± 0.58) x 108 2,90 x 109 6 
E10** THCGE (1.91 ± 0.12) x 107 3,06 x 108 16 
F8** GNGTA (3.59 ± 0.16) x 108 1,86 x 109 5 
H6** SGKSG (1.56 ± 0.06) x 108 1,57 x 109 10 
H8** TPQTK (4.73 ± 0.18) x 108 1,38 x 109 3 
H11** SASPG (4.54 ± 0.19) x 108 1,59 x 109 4 
Table 4: Amino acid substitution, genomic and capsid packaging titers of the selected 
clones and ratio of empty to full capsids of packaged GFP-vectors (*:pool after second 
selection round; **:pool after fourth selection round) 
 
To check the immune escaping phenotype of individual clones, six mutants A2, A11, B2, 
B10, C6 and H6 were chosen (carrying non-wt amino acids at all five positions) and 
subjected to detailed characterization. wtAAV1, wtAAV2 and K4 mutant (being the best 
mutant isolated by the same selection protocol out of an error prone PCR library in our lab) 
were used as controls to be compared with the selected mutants due to their immune 
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escape behavior. Being a different serotype that due to over 100 amino acid mutations in 
comparison to AAV2, AAV1 does not cross-react with anti AVV2 antibodies it was 
chosen as control to evaluate the immune-escaping phenotype of the selected mutants.  
Mutants packaged efficiently (see Table 4), the two clones isolated in the fourth selection 
round yielding the highest titers. The ratio between empty and full capsids varied from 4 to 
16 for the selected mutants which is in the same range as wtAAV2 (6.2). 
This demonstrates that, apart from the immune-escaping properties (characterized in the 
following paragraphs), the selection protocol selects mutants that efficiently package in the 
in vitro conditions of the screening procedure. 
 
6.3.2 Infection assays 
GFP-expressing vectors were analyzed for their immune escaping behavior. Increasing 
amounts of serum were incubated with GFP-vectors. HeLa cells were infected 2 h later and 
the percentage of transduced cells was measured 48 h later by cytofluorimetry.  
To make sure that the results were not influenced by differences in capsid or genomic 
titers, or by differences in iodixanol concentrations, these experiments were conducted 
with same amounts of genomic particles, total capsids and volume of iodixanol. 
In addition to the serum that was used for selections, mutants were tested on another 
neutralizing patient serum and on a highly concentrated intravenous immunoglobulin pool 
(IVIG) derived from more than thousand people. This IVIG pool represents an 
immunologic average of the human population.  
Serial dilutions of the sera were used to measure the neutralization curves of the vectors 
(see Figure 22). Since IVIG is more concentrated (50mg/ml IgG) than human serum (8 
mg/ml IgG), vectors were neutralized at lower concentrations, while 20% of serum 1 was 
not sufficient to neutralize the vectors completely.  
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Figure 22: Neutralization assays.  GFP-vectors were incubated with increasing amounts of 
serum 1 (upper panel), serum 2 (middle panel) or IVIG (lower panel) before infection of 
HeLa cells. The percentage of transduced cells was estimated 48h post infection by 
cytofluorimetry.. In the figures on the left,  wtAAV2 (black) is illustrated together with 
wtAAV1 (green), K4 mutant (blue), A11 mutant (orange) and H6 mutant (red). On the right, 
wtAAV2 is shown with A2 (dark yellow), B2 (olive), B10 (cyan) and C6 (dark red).  
 
 
Each mutant showed a characteristic phenotype on all three tested sera. The measurements 
with serum 1 were performed only as single experiment and without mutant A2 because 
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the serum stock was exhausted. However they are in accordance with those obtained for 
serum 2 and IVIG.   
To quantify the immune-escaping ability of the mutants, the amount of serum needed to 
halve the number of transduced cells (N50) was calculated. N50, relative N50 values (N50 
value of mutants divided by N50 of wtAAV2) and relative infectivities (infectivity of 
mutants divided by infectivity of wtAAV2) of the vectors are summarized in Table 5. B2 
mutant could not be tested on serum 1 due to serum stock exhaustion. 
 
vector wtAAV2 wtAAV1 K4 A2* B2* B10* C6** A11* H6** 
          
N50 (serum  1) 2.89 14.51 2.70 1.72 n.d. 6.08 5.81 4.02 7.45 
relative N50 (serum 1) 1 5.0 0.9 0.6 n.d. 2.1 2.0 1.4 2.6 
relative infectivity 
(serum 1) 
1 0.26 1.14 0.62 n.d. 0.86 1.08 0.79 1.14 
 
         
N50 (serum 2) 2.16 37.78 3.61 1.02 5.02 6.06 3.29 8.48 5.79 
relative N50 (serum 2) 1 17.5 1.7 0.5 2.3 2.8 1.5 3.9 2.7 
relative infectivity 
(serum 2) 
1 0.30 1.07 0.67 0.39 0.82 0.96 0.89 1.10 
 
         
N50 (IVIG) 0.21 4.05 0.24 0.20 0.05 0.70 0.33 0.45 1.08 
relative N50 (IVIG) 1 19.3 1.1 0.1 0.2 3.3 1.6 2.1 5.1 
relative infectivity  (IVIG) 1 0.25 1.08 0.73 0.43 0.71 0.89 0.72 1.13 
 
 
Table 5: N50 values, relative N50 values and relative infectivities without serum 
(compared to wtAAV2) of the tested vectors on patient sera 1, 2 and IVIG (*: mutant from 
pool after second selection;**: mutant from pool after fourth selection round). 
 
Taken together, the results reported in Figure 22 and Table 5 show that wtAAV2 is more 
infectious than wtAAV1, B2, A2, B10 and A11, equally infective as C6 and K4 and less 
infective than H6 in the absence of serum. N50 values demonstrate that A2 is more 
sensitive to neutralization by all three tested sera in comparison to wt AAV2. All other 
mutants escape neutralization better than wtAAV2. The only exceptions are K4 on serum 1 
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and A11 on IVIG. Mutants B2 and A11 show variations in their immune escaping 
phenotype when tested on different sera (N50: 0.2, 2.3 for B2; 1.4, 2.1 and 3.9 for A11). 
The H6 mutant shows highest transduction rates with and without serum. (The N50 of B10 
is 1.05-fold better on serum 2 but due to lower infection rate, the total amount of infected 
cells is higher for H6. The N50 of B10 is much lower on IVIG compared to H6. At high 
concentrations of serum 2, wtAAV1 is infecting more cells than H6.) wtAAV1 is showing 
highest N50 values on all three sera, varying between 5-fold and 19.3-fold superior to 
wtAAV2. 
 
6.3.3 Decoy assays 
Mutants A11, which showed best the best N50 value on serum 2, and mutant H6, which 
was the best on serum 1 and IVIG, were further investigated for their ability to bind human 
antibodies and to escape neutralization independently from their generic infectivity, 
packaging efficiency and efficiency of transgene expression. 
Same amounts of wtAAV2 were mixed with increasing amounts of wt, A11 or H6 empty 
particles (empty particles can be produced by a standard packaging method by transfecting 
293 cells without the ITR containing plasmid, for details see Materials and Methods 
section) and incubated with increasing amounts of serum 2 and IVIG. In this setting, 
antibodies contained in the serum are bound by viral particles in a measure that is directly 
proportional to their affinity for the capsids. If empty particles of one particular mutant are 
decoyed efficiently by serum antibodies, transduction rates determined by full wtAAV2 
particles will be higher. 
This experiment showed that at high serum concentrations, adding wt empty particles 
proportionally increased transduction rates more than addition of H6 and A11 empty 
capsids. Infection rates measured in the absence of serum were not affected by the addition 
of empty particles, indicating that no competition between empty and full capsids on 
cellular receptors responsible for the capsid internalization process had taken place. 
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Figure 23: Decoy assay for wtAAV2, A11 and H6 mutant.  Same amounts of wtAAV2 were 
mixed with 5-, 10- and 20-fold empty particles of wtAAV2 (top), H6 (middle) or A11 
(bottom). After incubation with serial dilutions of serum 2 (left graphs) and IVIG (right 
graphs), Hela cells were infected and transduction rates measures 48 h post infection. 
 
To quantify the results of Figure 23, N50 values of serum 2 obtained with wtAAV2, H6 or 
A11 particles were compared and are shown in Table 6. While the addition of wtAAV2 
empty capsids increased N50 values proportionally in a capsid dose-dependent manner 
(11.51 fold after adding 20-fold more capsids), the addition of empty H6 capsids had a 
reduced effect (8.53-fold) and the addition of A11 capsids resulted in no significant 
increase (1.63-fold). Strikingly, when the experiment was done with IVIG, the addition of 
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10x and 20x wt or H6 empty particles fully rescued AAV2 infectivity even at the highest 
IVIG concentrations. Despite preventing us from being able to calculate N50 values, this is 
a clear demonstration that while wt and H6 capsids can bind anti-AAV2 antibodies, A11 
capsids can efficiently escape recognition and therefore are inefficient decoys. 
In conclusion, showing a reduced decoy effect for H6 and almost no decoy effect for A11 
these results demonstrate that amino acid substitutions at the 5 randomized positions 
dramatically decrease the recognition by anti-AAV2 antibodies. Importantly, the amount of 
decrease changes considerably depending on the specific kind of amino acid substitution. 
Additional 
 empty capsids 
5x 10x 20x 
    
wtAAV2 2.95 5.48 11.51 
H6 2.08 2.70 8.53 
A11 0.88 1.46 1.63 
 
Table 6: Analysis of the decoy efficiencies of wtAAV2, H6 and A11 empty particles on 
serum 2. The x-fold increases of N50 values after addition of empty capsids are given. 
 
6.3.4 Multiple cell infection and Heparin inhibition assay 
To find out more about the mutants characteristics, I tested their infectivity on human and 
murine cell lines from different tissues and compared it to wtAAV2 and wtAAV1. Same 
amounts of GFP-vectors were applied to the cells and transduction rates were analyzed 48 
h post infection (see Figure 24).  
 
Figure 24: Total (B) and relative (B) infectivities of wtAAV2, A11, wtAAV1 and H6 on 
various cell types.  Same numbers of genomic particles were used to infect cells. 
Transduction rates were measured 48 h post infection via cytofluorimetry. For relative 
infectivities, wtAAV2 was normalized to 100% on each cell type. 
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The mutant A11 showed always lower infectivity, compared to wt varying between 6% on 
Hacat and 28% on HeLa cells. H6 was always superior to wtAAV2, while wtAAV1 was 
showing only 10% of wtAAV2 infectivity on HeLa but 89% on HEK293 cells. Being less 
infective in most cell types, AAV1 and wtAAV2 showed almost same infection rates on 
HEK293, suggesting a radically different tropism of these natural AAV serotypes. This 
hypothesis is in agreement with the results obtained infecting HeLa cells in the presence or 
absence of soluble heparin, an analogon of HSPG, the primary receptor of AAV2 (see 
Figure 25).  
 
Figure 25: Transduction efficiencies of wtAAV2 mutant A1, wtAAV1 and mutant H6 in 
the presence (black bars) or absence (white bars) of soluble heparin. The percentage of 
infected cells was quantified 48 h post infection via cytofluorimetry.(The tenfold dose of 
wtAAV1 was used to achieve comparable levels of infection) 
 
These results demonstrate that while AAV1 does not use the primary AAV2 receptor, the 
selected mutants do so, indicating that the five amino acid substitutions do not disrupt the 
original ability of the capsid to interact with natural receptors, maintaining an AAV2-
similar tropism.  
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7 Discussion II (Immune escape selections) 
 
Since a large majority of the human population is seropositive for AAV2 and other 
serotypes are not having the desired characteristics for some applications, me and others 
intend to engineer the AAV2 capsid in a way that disrupts binding sites of prevalent 
antibodies. Mutations introduced to redirect the viral tropism have been shown to decrease 
binding and neutralization by pre-existing antibodies (Wobus et al. 2000; Huttner et al. 
2003). This principle has been eventually exploited to generate ad hoc immune-escaping 
viral mutants by amino acid substitutions at the viral capsid surface by rational design or 
by directed evolution approaches (Lochrie et al. 2006; Maheshri et al. 2006; Perabo et al. 
2006). These studies identified several amino acid residues whose substitution decreased 
binding of human or rabbit antibodies. Mutants that retained infectivity of more than 1% 
after incubation with 6.7% serum (Maheshri et al. 2006), up to 10-fold increased infectivity 
on IVIG (Lochrie et al. 2006) and 5.5-fold increase on diluted serum (Perabo et al. 2006). 
Absolute data cannot be compared because different sera and read out systems were used, 
but all-over outcome of the formerly conducted trials was:  Despite providing an important 
proof of principle however, near-to-physiological range concentrations of antibodies could 
still neutralize transduction of these vectors. Therefore, I intended to create a new kind of 
viral library that would allow to enhance immune escaping properties of AAV2 derived 
vectors. 
Rational approach studies have shown that specific sites of the capsid are especially 
important for antibody recognition (Moskalenko et al. 2000). Until now, application of 
evolutionary methods for the generation of immune-escaping AAV vectors has employed 
libraries obtained by randomization of large portions of the viral capsid (Maheshri et al. 
2006; Perabo et al. 2006). Due to technical limitations these libraries can represent a 
maximum of one or two different amino acids at each position. These technical drawback 
and the results of my experiments underline the necessity to combine rational design and 
combinatorial methods to restrict regions to randomize and allow a complete screening of 
possible mutations. However the total biodiversity of libraries still is a limiting factor, 
indicating that consecutive iterations of selection procedures and combination of different 
kinds of libraries will be needed to further enhance mutants´ phenotype. 
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The observation that single amino acid differences are responsible for different aspects of 
the viral phenotype (packaging efficiency, infectivity and antibody recognition)  
demonstrates that the concept of complete randomization libraries is relevant not only for 
the generation of immune-evading mutants, but for any engineering goal. 
In the course of experiments it turned out that AAV1, differing in  more than hundred 
amino acids from AAV2 had the highest N50 values on all three sera but transduction rates 
were low on the tested cells. This points out that although alternative natural serotypes 
usually are strongly immune-escaping, the dramatic structural differences responsible for 
the immune-escaping phenotype determine considerable tropism-differences at the same 
time. This is limiting the possibility to use them to replace AAV2 vectors for the treatment 
of seropositive patients. The tropism profile obtained on 8 different cell types and by the 
analysis of heparin binding confirmed these differences in tropism. Both these experiments 
showed that conversely to AAV1, the selected mutants retain an AAV2 like tropism. 
The immune-escaping phenotype of the mutants was tested on two AAV2 seropositive 
patients sera and on IVIG, a pooled IgG-stock (immunoglobuline G) which represents the 
immunologic average of a human population. Phenotypes of the tested mutants showed 
some quantitative serum dependent variation but qualitatively it could be demonstrated that 
mutations that decrease neutralization tend to be effective independently from the kind of 
antibodies used.  
Mutant A11, which showed the best N50 value on serum 2, and mutant H6, which was the 
best on serum 1 and IVIG of the selected, were further investigated for their ability to bind 
human antibodies and to escape neutralization independently from their generic infectivity, 
packaging efficiency and efficiency of transgene expression by a decoy assay. The relative 
N50 values measured after addition of 20 x empty capsids of either wtAAV2, A11 or H6 
mutant demonstrated that binding of wt capsids to neutralizing antibodies of wt was 
stronger than for H6 mutant and A11 mutant respectively. The N50 values compared to 
infection without additional empty capsids were 1.35 fold higher for wtAAV2 than with 
H6 empty capsids and 7.06 higher than with A11 empty capsids, meaning that H6 mutant 
is binding to anti AAV2 antibodies less efficiently than wt but especially A11 has lower 
antibody recognition phenotype. H6 was showing enhanced immune escape although 
having a relatively high decoy capacity. This might be explained with binding of the 
antibodies without being as efficiently neutralized as wtAAV2. 
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Finally, it is important to note that after performing four selection rounds, the surviving 
pool of mutants was not dominated by redundant clones. Despite the presence of a number 
of identical or similar clones appearing in multiple copies, the biodiversity of the pool was 
still remarkable, suggesting that further selection rounds or increased selection stringency 
during the screening procedure could lead to the isolation of further optimized mutants, 
which for example combine high infectivity with low antibodies recognition. After 
optimization of the here mutated amino acid residues of the viral capsid is achieved, codon 
randomization could be extended to additional residues in order to improve the immune-
escaping phenotype. 
To yield an immune escaping mutant that is not at all recognized by patient serum would 
need Further understanding of antibody binding sites, optimization of more residues, 
combination of different libraries and consecutive evolution steps can in future further 
enhance selection results.  
Even if neutralization is not completely abolished, lower recognition can be useful for 
therapy vectors and may be combined with targeting mutants to optimize vectors for 
specific applications. Bringing together vector variants of with different beneficial 
characteristics would lower the needed doses for therapy, diminish unwanted side effects 
and lead to a more efficient delivery of the genetic cargo to the desired target tissue. 
The results gathered within this work demonstrate that for the generation of immune-
escaping mutants, besides identifying immunogenic residues of the viral capsid it is 
fundamental to optimize the amino acid substitutions at these sites. The specific chemical 
characteristics of each single residue have dramatic consequences on structural and 
biological properties of the capsid.  
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8 Conclusions and outlook 
 
Despite promising results of first clinical trials with gene therapy vectors they are not suitable 
for routine application. The breakthrough of such applications in clinical routine depends on 
the availability of efficient and safe gene delivery vector. Although natural viruses are 
inspiring elegant technical solutions, characteristics ideally required of gene therapy viral 
particles often differ from those of original structures. Therefore, depending on the envisioned 
utilisation, biological viruses demand different levels of manipulation before they can be 
successfully employed. For example it is desirable to enhance production yields, stability, 
control tropism and avoid neutralization by pre-existing antibodies. Incomplete understanding 
of capsid biology and of the correspondence between protein architecture and function 
currently limits the development. 
Application of modern molecular biology techniques is contributing to understand the 
principles of particle assembly, immunogenicity, genome encapsidation and capsid infection 
biology. Rational design and combinatorial approaches are used to relate particle architecture 
to function and eventually alter it. Understanding how capsid proteins interact with each 
other, with the viral genome and with host cells will benefit a broad range of disciplines, from 
clinical virology to gene therapy and other diverse biotechnology applications of viral 
nanoparticles. 
Engineering techniques like those described in my work allow the exploitation of the potential 
and plasticity of protein chemistry to tailor vectors for the specific requirements of different 
applications. Pushing back the boundaries of molecular engineering of viral nanoparticles, 
further refinement and use of these methods promise to provide solutions that transcend 
technical limitations imposed by natural systems and classical modification approaches. 
Eventually, this will facilitate the transition to a phase in which nanoparticles devices can be 
manipulated at will, overcoming drawbacks of systems that too closely resemble the original. 
In the future, especially the combination of rational design and combinatorial techniques and 
more knowledge about capsid biology promises to enable scientists to develop new vectors 
with even more patient- and application-specific phenotypes. 
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9 Materials 
9.1 Chemicals, solutions and enzymes 
Substance     Supplier 
Agarose    Sigma, Deisenhofen, Germany 
Ampicillin    Sigma, Deisenhofen, Germany 
Aqua bidest.     Millipore, Billerica, Germany 
Benzonase    Merck, Darmstadt, Germany 
Bovine Serum Albumine  AppliChem, Darmstadt, Germany 
D-MEM medium    Invitrogen Corporation, Germany 
Etidium bromide    Roth, Karlsruhe, Germany 
Fetal Calf Serum   Invitrogen Corporation, Karlsruhe, Germany 
Heparin    B. Braun Melsungen AG, Germany 
HEPES     Roth, Karlsruhe, Germany 
Iodixanol    Sigma, Deisenhofen, Germany 
MassRuler DNA Ladder Mix  MBI Fermentas GmbH, St. Leon-Rot, Germany 
Methanol     Roth, Karlsruhe , Germany 
PBS     Invitrogen Corporation, Karlsruhe, Germany 
Penicillin/Streptomycin  Invitrogen Corporation, Karlsruhe, Germany 
Phusion DNA-Polymerase  Finnzymes, Keilaranta, Finland 
Proteinase K     Merck, Darmstadt, Germany 
RPMI 1640 medium    Invitrogen Corporation, Germany 
Sodium Chloride    Riedel-de Haën, Seelze, Germany 
Sodium Dodecyl Sulfate (SDS) Merck, Darmstadt, Germany 
Tris     Merck, Darmstadt, Germany 
TritonX-100     Sigma, Deisenhofen, Germany 
Trypsin-EDTA    Invitrogen Corporation, Karlsruhe, Germany 
Tween 20     Merck, Darmstadt, Germany 
 
If not mentioned the chemicals were bought from Sigma-Aldrich, Taufkirchen, Germany; 
Merck, Darmstadt, Germany or Carl Roth GmbH & Co., Karlsruhe, Germany. 
DNA-restriction and -modifying enzymes not listed were bought from MBI Fermentas, St. 
Leon-Rot, Germany 
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9.2 Standard kits 
DNeasy® Tissue Kit      Qiagen, Hilden, Germany 
EndoFree® Plasmid Kits     Qiagen, Hilden, Germany 
Gel Extraction Kit      Qiagen, Hilden, Germany 
PCR Purification Kit      Qiagen, Hilden, Germany 
Qiaex II Gel Extraction Kit      Qiagen, Hilden, Germany 
Light-Cycler-FastStart DNA Master SYBR Green I Roche, Mannheim, Germany 
 
9.3 Plasmids 
p587Lib7: insertion-library plasmid, contains the AAV-2 Rep and Cap encoding regions 
flanked by the viral ITRs 
pdegen5Lib: degeneration library plasmid, randomised at positions 449, 458, 459, 493 and 
551 of VP1 counting, contains the AAV-2 Rep and Cap encoding regions 
pRC:  AAV based helper plasmid containing the AAV-2 Rep and Cap coding regions 
but lacking the viral ITRs (Girod, Ried et al. 1999) 
pRC”Kotin”: AAV based helper plasmid containing the AAV-2 Rep and Cap coding 
pXX6-80:  kindly received as gift from J. Samulski and encoding for the Adenoviral genes 
VA, E2A and E4 (Grimm, Kern et al. 1999) regions but lacking the viral ITRs, 
containing SnaBI and BsiWI cloning sites 
scGFP:  GFP gene controlled by human cytomegalo virus promoter; a deletion in the 
terminal resolution sites interferes with strand displacement resulting in a self 
complementary genome, which is packaged into viral capsid (Hacker, 
Wingenfeld et al. 2005) 
wtAAV-2:  contains the AAV-2 Rep and Cap encoding regions flanked by the viral ITR’s 
(Girod, Ried et al. 1999). 
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9.4 Primers 
Oligonucleotides manufactured by Metabion, Martinsried, Germany are listed in 5’→3´ 
direction. 
Primers for wtAAV: 
3201-forward 
5’ – GGTACGACGACGATTGCC – 3’ 
4066-reverse 
5’ – ATGTCCGTCCGTGTGTGG – 3’ 
 
Primers for rAAV (eGFP): 
EGFP-1 forward 
5’ – GCTACCCCGACCACATGAAG – 3’ 
EGFP-1 reverse 
5’ – GTCCATGCCGAGAGTGATCC – 3’ 
 
Primers for Amplification of selected clones: 
BsiWI- forward 
5’ – TACCAGCTCCCGTACGTCCTCGGC – 3’ 
New SnaBI-reverse 
5’ –CGCCATGCTACTTATCTACG– 3’ 
 
Primers for the generation of pdegen5Lib: 
449,458,459 degen-forward 
5´-GCAGAACANNSACTCCAAGTGGAACCACCACGCAGNNSNNSCTTCAGTTT-3´ 
449,458,459 degen-reverse 
5´-AAACTGAAGSNNSNNCTGCGTGGTGGTTCCACTTGGAGTSNNTGTTCTGC-3´ 
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493 degen-forward  
5´-GACATCTNNSGATAACAACAACAGTGAATACTCG-3´ 
493 degen-reverse 
5´-CGAGTATTCACTGTTGTTGTTATCSNNAGATGTC-3´ 
551 degen-forward  
5´-GGCTCAGAGAAAACANNSGTGGACAATG-3´ 
551 degen-reverse 
5´-TCCACSNNTGTTTTCTCTGAGCCTTGC-3´ 
 
9.5 Antibodies and sera 
• A20 (AAV2-capsid antibody, IgG3), monoclonal mouse hybridoma supernatant (DKFZ 
Heidelberg, PD Dr. J. Kleinschmidt)  
• B1 (VP3-specific antibody), monoclonal mouse hybridoma supernatant (DKFZ Heidelberg, 
PD Dr. J. Kleinschmidt)  
• Biotin conjugate Streptavidin (Dianova) 
• Biotin-SP-conjugated rabbit anti mouse antibody (Dianova) 
• Intratect (pooled human IgG stock, 50mg/ml, Biotest) 
• Serum 1 patient Serum 
• Serum 2 patient serum 
 
9.6 Bacteria strains 
For chemical transformation: E.coli DH5α: F-, lac1-, recA1, endA1, hsdR17, Δ(lacZYA-
argF), U169, F80dlacZΔM15, supE44, thi-1, gyrA96, relA1; (Hanahan 1983) 
For electrical transformation: Electroten-Blue Electroporation Competent Cells: Δ(mcrA)183 
Δ(mcrCB-hsdSMR-mrr)173 endA1 supE44 thi-1 recA1, gyrA96 relA1 lacKanr 
[F´ proAB lacIqZΔM15 Tn10 (Tetr)], Stratagene, La Jolla, USA 
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9.7 Eukaryotic cells 
BLM, MV3: human melanoma cell line; RPMI with 10% FCS, 100 units/ml of Pen/Strep 
and 1% of non-essential amino acids 
Fibroblasts: primary human Fibroblasts; isolated from healthy female skin tissue; DMEM 
with 10% FCS and 100 units/ml of Pen/Strep 
HaCat: human keratinocyte cell line; spontaneously immortalized; DMEM with 10% 
FCS and 100 units/ml of Pen/Strep 
HEK293: human kidney cells; transformed with adenovirus 5 DNA, containing E1A and 
E2; D-MEM with 10% FCS and 100 units/ml of Pen/Strep 
HeLa: human cervix adenocarcinoma; D-MEM with 10% FCS and 100 units/ml of 
Pen/Strep  
Hom01; MelA, M001: primary human melanoma cells; DMEM with 10% FCS and 100 
units/ml of Pen/Strep 
Keratinocytes: human primary cells; DMEM with 10% FCS and 100 units/ml of Pen/Strep 
MDA: human breast cancer cell line, DMEM with 10% FCS and 100 units/ml of 
Pen/Strep 
NIH3T3: murine embryonic fibroblast cell line, DMEM with 10% FCS and 100 units/ml 
of Pen/Strep 
 
9.8 Data treating software 
Microsoft Office; Roche Molecular Biochemicals Lightcycler Software v3.5; Elisa Reader 
SofMax Pro v1.2.0; Origin 8; Adobe Photoshop CS2; Freeware:  BioEdit; pDraw; Chromas
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9.9 Laboratory equipment, disposables 
Equipment    Supplier 
48well Multiwell (polystyrene)  Beckton-Dickinson GmbH, Heidelberg 
5-6B Centrifuge   Beckman Instruments GmbH, München, Germany 
Balance Adventure Pro   Ohaus Corporation, NJ, USA 
Spectophotometer  
BioRadSmartSpec3000   Bio-Rad laboratories GmbH, München, Germany 
Cell culture plastic ware   Beyer GmbH, Düsseldorf, Germany 
Centrifuge 5415 D    Eppendorf AG, Hamburg, Germany 
Centrifuge 5810 R    Eppendorf AG, Hamburg, Germany 
Dialysisfilter VS (0.0025 µm)  Milipore AG, Zug, Switzerland 
Electrophoresis Unit   
Sub-Cell GT Gel    Bio-Rad laboratories GmbH, München, Germany 
Emax Precision Microplate Reader  Molecular Devices GmbH, München, USA 
FACSCalibur     Beckton-Dickinson GmbH, Heidelberg 
Gene Pulser II    Bio-Rad laboratories GmbH, München, Germany 
Heater/Magnetic Shaker  
Heidolph MR 3001    Heidolph Instruments, Schwabach, Germany 
Hera -80° freeze    Heraeus, Sepatech GmbH, Osterode, Germany 
Incubator Shaker Innova 4430  New Brunswick Scientific, Inc, NJ, USA 
Light Cycler     Roche Diagnostics GmbH, Mannheim, Germany 
Light Microscope Axiovert 25 CFL  Carl Zeiss Jena GmbH, Göttingen, Germany 
Mamalian Incubator Hera Cell 150  Heraeus, Sepatech GmbH, Osterode, Germany 
Neubauer Haematocytometer LO Laboroptik GmBH, Friedrichsdorf, Germany 
pHmeterSevenEasy    Mettler-Toledo GmbH, Schwerzenbach, Switzerland 
Polyesterol tubes 50 ml   Beckton-Dickinson GmbH, Heidelberg 
Pump P-1    Amersham Pharmacia Biotech, Freiburg, Germany 
Sorval Ultracentrifuge Combi  DuPont GmbH, Bad Homburg 
Thermomixer Comfort   VWR International GmbH, Darmstadt, Germany 
Therocycler T3000    Biometra, Göttingen, Germany 
Vortex Genie2    Scientific Industries, Inc, NY, USA 
Waterbath Medingen W6   Medigen GmbH, Martinsried, Germany 
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Electroporationcuvettes, 0,1 cm Bio-Rad laboratories GmbH, München, Germany 
Sterile filters 0.22μm, 0.45μm  Schleicher&Schuell GmbH, Dassel, Germany 
 
General laboratory ware was bought at VWR International GmbH, Darmstadt, Germany.
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10 Methods 
10.1 Bacteria culture 
10.1.1 Cultivation of bacteria 
Bacteria were grown at 37°C with LB medium overnight while vigorously shaking.  
For growing the bacteria on plates, 15 g/l Agar was added to LB medium for solidification.  
For transformed bacteria with resistance to ampicillin, 50 mg/l ampicillin was added to the 
medium. 
 
LB medium (1 l):  
10 g Tryptone 
5 g Yeast extract 
5 g NaCl 
ad 1 l H2O 
 
10.1.2 Glycerol stocks 
1ml of overnight culture was spun down at 2500 rpm for 1 min in a table centrifuge and 
resuspended in 1ml LB containing 50% glycerol before freezing at -80°C.  
 
10.1.3 Preparation of chemically competent bacteria 
Bacteria strain DH5α was grown at 37°C and vigorous shaking (200 rpm) overnight in 8 ml of 
LB medium. 10 hours later 1 ml was transferred into 30 ml of LB medium and the bacteria 
were grown until an optical density (OD600) of 0,7. Incubation on ice was performed for 30 
min followed by centrifugation at 3200 rpm for 15 min at 4°C. Pellet was re-suspended in 10 
ml of cold TFBI buffer. Incubation on ice was done and followed by a centrifugation which 
was performed as before. The pellet was re-suspended in 3 ml of cold TFB II. 
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TFB I buffer (200 ml):  
30 mM potassium acetate 
100 mM CaCl2 
15 % glycerol 
ad 190 ml H2O 
Autoclaved, than addition of sterile filtered: 
50 mM MnCl2 
 
TFB II buffer (50 ml):  
10 mM MOPS 
75 mM CaCl2 
10 mM KCl 
15 % glycerol 
ad 50 ml H2O 
 
10.1.4 Chemical transformation of bacteria 
200 μl of competent bacterial suspension was transferred into the reaction tubes already 
containing the plasmid which should be introduced (coding for resistance to ampicillin). After 
vortexing the suspension was incubated for 45 sec at 42°C. Afterwards, 1 ml of LB medium 
was added cells were shook at 200 rpm and 37°C for 30 min. Bacteria were plated onto 
ampicillin containing LB-plates (50 μg/ml) and incubated overnight at 37°C. 
 
10.1.5 Preparation of electrocompetent bacteria 
Pipet tips, centrifuge tubes and reagents were precooled to 4°C. 2 l baffled flasks with 400 ml 
prewarmed YENB were used to grow bacteria. A colony of freshly streaked Electroten blue 
was inoculated with 100 ml YENB medium overnight without letting it grow to full density.  
The next day, 2 ml of overnight culture were inoculated in 400 ml YENB and shook until 
reaching OD600 of 0,7. This culture was split into four additional flasks and grown again. 
Directly after reaching OD600 of 0,7, bacteria were cooled in ice water and centrifuged 10 min 
at 4000 x g. Pellets were washed twice with 200 ml water and one additional time with 50 ml 
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10 % glycerol. After a last centrifugation, cells were resuspended in 1ml of 10 % glycerol, 
split into 40 µl aliquots and frozen in liquid nitrogen before being transferred to -80°C. 
(YENB medium: 0.75% Bacto yeast extract; 0.8% Bacto nutrient broth (salt free)) 
 
10.1.6 Electrical transformation of bacteria 
Library ligation DNA was dialyzed against water for at least 2h before transformation. Pipet 
tips and cuvettes were cooled to 4°C, SOC medium was prewarmed to 37°C before starting. 
40µl of chemically competent bacteria were thawed on ice, mixed with ¼ of the library 
ligation and cautiously pipetted into the cuvette. The electroporation was performed at 
1,85kV, 600Ω and 25µFD, resulting in a time constant between 11 and 13. 1 ml SOC medium 
was added directly and the cells were shook for 1h at 37°C, before transfer of the cells to 
500ml of LB medium and plating a defined dilution of the reaction to estimate the 
biodiversity. A glycerol stock was done and the DNA was extracted the next day using a 
Qiagen maxi kit. 
 
SOC medium: 
20 g Tryptone 
5 g  Yeast extract 
5 g  NaCl 
Ad 1 l  Water 
Add  10 ml of filter-sterilized 1 M MgCl2 , 10 ml 1 M MgSO4, 20 ml 20% (w/v) glucose 
 
10.2  DNA techniques 
10.2.1 Plasmid amplification and extraction, DNA cleanup 
For plasmid amplification, extraction and DNA cleanup suitable Qiagen kits were used 
following the manufacturers protocols.  
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10.2.2 DNA quantification 
DNA concentration was measured using a BioRadSmartSpec 3000 spectrophotometer. 
Quantification is made by measuring absorbance at 260nm. Low concentrated DNA-probes 
were analyzed on agarose gels. 
10.2.3 Restriction enzyme digest 
Digestion with restriction enzymes was performed according to the manufactures instructions 
in a 20 μl solution containing 1 μg of DNA, 1-10 U of restriction enzyme per 1 μg of DNA 
and 1x buffer. 
10.2.4 Agarose gel electrophoresis 
Stock solution for agarose gels was prepared by adding the desired percentage of agarose to 
the TBE Buffer mixed with ethidium bromide (0.25 μg/ml).TBE buffer was then added to the 
chamber. Electrophoresis was performed at 75 V and 200 mA. 
 
TBE Buffer (10x; 5 l):  
540 g Tris Base 
275 g Boric Acid 
200 ml of 0.5 M EDTA pH 8.0 
ad 5 l H2O 
10.2.5 Sequence analysis 
Sequencing of bacterial clones was performed (Qiagen, Hilden, Germany) after DNA 
extraction and PCR amplification from viral preparations (viral libraries and viral pools after 
selection) using primer 4066. Single viral genomes were obtained by amplification of viral 
DNA (Primers: New SnaBI-reverse; BsiWI-forward), cloning amplified DNA into 
pRC”Kotin” backbone, transformation into bacteria and picking single colonies of the plated 
cultures.  
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1x Standard PCR-premix: 
1 µl  dNTPs (200µM each) 
10 µl  5x Phusion reaction buffer 
2 µl  New SnaBI-reverse (10 µM) 
2 µl  BsiWI-forward (10 µM)  
5 µl  template DNA (DNeasyeluate) 
Ad 49.5 µl water 
0.5 µl  Phusion Polymerase 
 
Standard amplification PCR-cycling NS1/Bb (3°C/sec): 
   Denaturation 98°C 30´´ 
   Amplification 98°C 10´´ 
     56°C 20´´ 34 x 
     72°C 30´´   
   Elongation 72°C 10´ 
   Cooling 4°C ∞ 
 
 
10.2.6 Cloning of the pdegen5Lib library 
The pwtAAV2 Plasmid (2 µg/µl) was used as a template for the following PCRs. When PCR-
products were used as templates, they were purified by gel extraction before. All PCR steps 
were programmed with a slope of 3°C/sec. The PCR-process was executed in the order given 
below. 
449,458, 459-493premix: 
1 µl  dNTPs (200µM each) 
10 µl  5x Phusion reaction buffer 
2 µl     449,458,459 degen-forward  (10 µM) 
2 µl     493 degen-reverse(10 µM)  
2 µl  wtAAV2 (1:10) 
Ad 49.5 µl water 
0.5 µl  Phusion Polymerase 
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PCR-Cycling NS1/Bb 5 sec elongation: 
   Denaturation 98°C 30´´ 
   Amplification 98°C 10´´ 
     56°C 20´´ 34 x 
     72°C 5´´   
   Elongation 72°C 10´ 
   Cooling 4°C ∞ 
 
493-551 premix: 
1 µl  dNTPs (200µM each) 
10 µl  5x Phusion reaction buffer 
2 µl     493 degen-forward  (10 µM) 
2 µl     551 degen-reverse (10 µM)  
2 µl  wtAAV2 (1:10) 
Ad 49.5 µl water 
0.5 µl  Phusion Polymerase 
PCR-Cycling NS1/Bb 5 sec elongation 
 
449-551 premix 
1 µl  dNTPs (200µM each) 
10 µl  5x Phusion reaction buffer 
10 µl    449,458,459 degen-forward  (10 µM) 
10 µl    551 degen-reverse (10 µM)  
1 µl  449-493 PCR-product  
1 µl  493-551 PCR-product  
Ad 49.5 µl water 
0.5 µl  Phusion Polymerase 
PCR-Cycling NS1/Bb 5 sec elongation 
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BsiWI-449 premix 
1 µl  dNTPs (200µM each) 
10 µl  5x Phusion reaction buffer 
2 µl     BsiWI-forward (10 µM) 
2 µl     449degen-reverse (10 µM)  
1 µl  wtAAV2 (1:10) 
Ad 49.5 µl water 
0.5 µl  Phusion Polymerase 
Standard amplification PCR-cycling NS1/Bb 
 
551-NewSnaBI premix 
1 µl  dNTPs (200µM each) 
10 µl  5x Phusion reaction buffer 
2 µl     551degen forward  (10 µM) 
2 µl     New SnaBI-forward (reverse)(10 µM)  
1 µl  wtAAV2 (1:10) 
Ad 49.5 µl water 
0.5 µl  Phusion Polymerase 
Standard amplification PCR-cycling NS1/Bb 
 
449-NewSnaBI premix 
1 µl  dNTPs (200µM each) 
10 µl  5x Phusion reaction buffer 
2 µl     449 degen forward  (10 µM) 
2 µl     New SnaBI-reverse (10 µM)  
1 µl  449-551 PCR-product 
1 µl  551-New SnaBI PCR-product 
Ad 49.5 µl water  
0.5 µl  Phusion Polymerase 
Standard amplification PCR-cycling NS1/Bb 
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BsiWI-NewSnaBI premix 
1 µl  dNTPs (200µM each) 
10 µl  5x Phusion reaction buffer 
2 µl    BsiWI-forward (10 µM) 
2 µl    New SnaBI-reverse (10 µM)  
2 µl  BsiWI-449 PCR-product 
1 µl  449-New SnaBI PCR-product 
Ad 49.5 µl water  
0.5 µl  Phusion Polymerase 
Standard amplification PCR-cycling NS1/Bb 
 
The insert was digested with BsiWI and SnaBI and ligated into pwtAAV2 backbone (s. 
library ligation). After ligation, the pdegen5Lib was directly dialyzed and cells were 
transformed (s. Electrical Transformation of Bacteria). Virus was packaged on HEK293 cells 
as described above. The viral library was sequenced and the chromas file was checked for 
complete randomization. A biodiversity of 5.5x106 was measured by extrapolation of the 
number of bacterial colonies after transformation. The diversity limiting step in the library 
generating procedure is the efficient ligation and transformation of PCR-generated library 
variants into plasmids and afterwards bacterial cells. The number of total bacteria transformed 
is estimated by streaking out samples of the bacterial library and equalizing the number of 
clones to the number of different variants existing in the library. This is feasible due to the 
enormous number of DNA-variants compared to the number of bacterial clones. 
 
 
10.2.7 Library ligation 
300 ng of wt-backbone (wtAAV2-plasmid, digested with SnaBI and BsiWI) was mixed with 
200 ng insert and heated to 50°C  for 10 min before adding 100 µl T4 ligation mix, containing 
1µl of T4 Ligase. The reaction mixture was incubated at 16°C overnight. The reaction was 
stopped by heat inactivation at 65°C for 10 min.  
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10.3  Eukaryotic cell culture 
10.3.1 Cultivation of cells 
Cells were cultivated at 37°C and 5% CO2 in humid atmosphere.  
Cells were grown with antibiotic Penicillin/Streptomycin. 
 
10.3.2 Trypsinisation 
Cells were washed with PBS, trypsin (0.5 g/l) was added in an amount that covered the 
bottom of the plates, followed by an incubation at 37°C (duration depending on the cell line). 
When the cells detached from the plate reaction was stopped with medium containing 10% 
FCS. 
 
10.3.3 Seeding / passaging 
Cells were transferred into a new plate or flask containing fresh medium that was warmed up 
to 37°C. Agitation of the plate with movements in cross were made in order to spread the cells 
homogeneous. 
 
10.3.4 Freezing and thawing cells 
Cells were trypsinized, gathered in a falcon tube and pelleted at 1200 rpm. Supernatant was 
removed and cell pellet was resuspended with freezing solution. 1 ml of cell suspension was 
added to each freezing vial. Cells were then directly transferred to -80°C in an isopropanol 
containing freezing carrousel. The next day, cells were transferred to liquid nitrogen. 
For thawing the cells, the freezing vials were taken out of liquid nitrogen storage and the 
suspension let to thaw at 37°C, after which it was taken to a flask or plate with prewarmed 
medium. 
 
Freezing solution:  
90% FCS 
10% DMSO 
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10.3.5 Cell counting 
After trypsinizing and diluting the cells, 10 μl were transferred into a hematocytometer. The 
number of cells in each of the four squares was counted and an average was made for more 
precise determination. The number of cells (n) determined equals n x 104per ml. 
 
10.4  Production of AAV2-vectors 
10.4.1 AAV-vector packaging 
Five 15 cm petri dishes were used for seeding 7.5 x106 HEK293 cells/plate in 25 ml DMEM 
with Glutamax plus 10% FCS and 1% P/S. 
24 hours later (cells showed approximately 80% confluence) fresh medium (10% FCS and 1% 
P/S) was added. 
The transfection was performed 2 hours later using 37.5 μg of DNA per plate. 
 
For five plates rAAV (scGFP): 
5 ml   250 mM CaCl2 
37.5 μg  pRC 
37.5 μg  scGFP 
112.5μg  pXX6-80  
5 ml   HBS-Puffer 
 
For wtAAV/AAV-libraries: 
5 ml   250 mM CaCl2 
75 μg   wtAAV2 or AAV library plasmid 
112.5   μg pXX6-80  
5 ml   HBS-Puffer 
 
After adding HBS buffer, the solution has to be vortexed directly. 
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HBS-buffer 
Weighted: 
5.95 g  HEPES 
8.18 g  NaCl 
1.5 ml  0.5M NaP (pH 7.29) 
ad 400 ml with bought SIGMA water (adjust pH to 7.1) 
 
Exactly 2 minutes after vortexing the solution was dropped onto the cells. 24 hours later 
(approximately 100% confluence), medium was exchanged to 20ml DMEM with Glutamax 
plus 2% FCS and 1% P/S. 
The cells were harvested 48 h post transfection by scraping them from of the plate, collecting 
them in a conic centrifuge tube and centrifuging them at 3000 rpm for 15min. The supernatant 
was wasted and the pellet resuspended in 7.5 ml of lysis buffer (150 mM NaCl; 50 mM 
Tris/HCl, pH 8.5). The cells were 3 times submitted to thermal shock by using liquid nitrogen 
and a water bath at 37°C. 
To get rid off cellular DNA or RNA the suspension was treated with 50 U of Benzonase per 
ml of suspension at 37°C during 30 min. The falcons were centrifuged for 30 min at 4°C and 
4000 rpm; the solution was transferred into a new falcon (pellet was discarded) and filled up 
with PBS, centrifuged again for 30 min at 4°C and 4000 rpm. The outcome of this procedure 
is called crude lysate and was used for selections. 
 
10.4.2 Iodixanol gradient purification 
An iodixanol step gradient centrifugation was performed using four different iodixanol 
solutions (see below for the composition of each solution) and PBS with magnesium and 
potassium for equilibration of the tubes. A needle reaching the bottom of the tube was used to 
slowly add (using an “Amersham Biosciences Pump P-1”) all the solutions starting with 
lowest density solution. The centrifugation was performed at 63000 rpm for 1h at 18°C and 
subsequently the 40% iodixanol phase harvested.  
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15% Iodixanol : 25% Iodixanol : 
10xPBS  5 ml  10xPBS  5 ml  
2 M MgCl2  25 μl 2 M MgCl2  25 μl 
1 M KCl 125 μl 1 M KCl 125 μl 
5 M NaCl 10 ml  Optiprep 20 ml  
Optiprep 12.5 ml  0.5% phenol red 100 μl 
0.5% phenol red 75 μl Sigma water ad 50 ml  
Sigma water ad 50 ml  
 
40% Iodixanol:  60% Iodixanol:  
10xPBS  5 ml  2 M MgCl2  25 μl 
2 M MgCl2  25 μl 1 M KCl 125 μl 
1 M KCl 125 μl Optiprep 50 ml  
Optiprep 33.5 ml  0.5% phenol red 25 μl 
Sigma water ad 50 ml  
 
10.4.3 Virus titration 
Genomic titer 
For extraction of the DNA from the viral particles a “QiagenDNeasy Tissue Kit” was used 
and the protocol for “Isolation of Total DNA from Cultured Animal Cells” was performed. 10 
μl of virus were diluted in 200 μl of PBS. The genomic titer was then determined by 
quantitative real time PCR (qPCR) using a “Roche LightCyclerFastStart DNA Master SYBR 
Green I” kit. The probes were prepared as described below.   
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a) wtAAV genomic titration 
Primers: 3201-forward (sense); 4066-reverse (anti-sense) 
Volumes per probe: 
LCFastStart DNA Master 2 μl 
Sense (100 μM)   0.1 μl 
Antisense (100 μM)   0.1 μl 
MgCl2 (25 mM)  3.2 μl 
H2O    12.6 μl 
2 μl DNA extracted from 200µl of 
viral preparation  
 
Cycling:  
   Denaturation 95°C 15´ 
   Amplification 95°C 10´´ 
     60°C 3´´  34 x (20°C/sec) 
     72°C 35´´   
   Melting curve 68°C→95°C 0.05°C/sec 
 
b) rAAV (eGFP) genomic titration  
Primers: EGFP-1 forward (sense); EGFP-1 reverse (anti-sense) 
Volumes per probe: s. wtAAV genomic titration 
Cycling:  
   Denaturation 95°C 10´ 
   Amplification 95°C 10´´ 
     63°C 3´´ 50 x (20°C/sec) 
     72°C 20´´  
   Melting curve 67°C → 95°C 0.1°C/sec 
 
By comparison with the standards the program calculates the amount of DNA in the probes. 
The standards were diluted from according plasmid stocks with photometrical detected DNA 
concentration. 
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10.4.4 Capsid titer (ELISA) 
The determination of the capsid titer was performed using the anti AAV A20 antibody. Based 
on the genomic titer and the fact that the capsid titer is normally 10x higher, eight serial 
dilutions were made in order to obtain concentrations in the linear range of the ELISA 
(between 107and 1010 capsids/µl). 
100 μl of PBS, serial dilutions of Control (empty AAV capsids), and specimen (diluted in 
PBS) were pipetted separately into the wells of a 96-well plate. The plate was sealed with 
parafilm and incubated for 1h at 37°C or at 4°C overnight. 
A wash step was performed 3 times: 3 times the contents of the 96-well plate were emptied 
and each well was filled with 200 µl wash buffer, incubated for approximately 5 sec and then 
the contents emptied again. Afterwards the wells were incubated with 200µl of blocking 
buffer for 1h at 37°C.  
Then, wells were incubated with 100 μl of A20 antibody (1:10, Hybridoma supernatant) in 
blocking buffer for one hour. Three washing steps were repeated as described above. 
The second antibody (1:25000, α-mouse IgG-Biotin conjugate) was pipetted into each well, 
and incubated for 1h at 37°C. Another 3 washing steps were performed just as described 
before and 100 μl of streptavidin peroxidase conjugate were pipetted into each well and 
incubated for 1h at 37°C. 
After another 3 washing steps and two additional washing steps with 200 µl of water, 100 μl 
of ready-to-use TMB- substrate was activated with 30% H2O2and added into each well. 
Incubation was performed for 5-15 min at room temperature. Color reaction was then stopped 
by adding 50μl of 1M H2SO4 into each well and the intensity of the color reaction was 
measured using a photometer at 450 nm. 
 
Wash buffer: PBS, 0,05% Tween 20 
Blocking Buffer: Wash Buffer containing 3% BSA, 5% Sucrose 
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10.5  Infection assays and selection procedures 
10.5.1 Titration of adenovirus on BLM 
2.5x105 BLM cells were seeded in a 6-well plate and infected 24 h later with various amounts 
of Adenovirus and 2x103 genomic particles per cell wtAAV2. 48 h post infection, viral 
progeny was harvested and measured by qPCR.  
 
10.5.2 Decoy assay on fibroblasts and keratinocytes 
2.5x105 BLM cells, 1x105 primary human fibroblasts or 5x105 primary human keratinocytes 
were seeded in 6-well plates. 24 h later, 106 viral genomic genomic particles of the display 
library were incubated in 1 ml of medium for 2 h either in empty wells, above fibroblasts or 
keratinocytes. BLM cells were infected in the meanwhile with 2800 pfu/cell of adenovirus. 
After 2 h, the adenovirus-containing medium was wasted and the library-containing medium 
was transferred from empty-, fibroblast or keratinocytes wells to BLM cells. 48 h post 
infection, viral progeny was harvested and relative amounts per µl were measured by qPCR.  
 
10.5.3 Selection protocol for BLM-specific mutants 
2.5 × 105 human primary skin fibroblasts and BLM cells were seeded in 6-well plates and 
fibroblasts infected 24 h later with 104; 103 genomic particles of AAV display library. The 
culture supernatant was harvested 2 h post infection and used to infect BLM cells. At the 
same time, BLM cells were superinfected with 2800pfu/cell of adenovirus type 5. 48 h post 
infection, cells were harvested by trypsinisation and viral progeny was obtained by three 
cycles of freeze-thaw and spin-down of the cell debris. Adenovirus was heat-inactivated at 
60°C for 30 minutes. After each selection round, the genomic titer of these preparations was 
monitored by qPCR using the “wtAAV genomic titration” protocol and eventually used for 
further selection rounds. Selection pressure was adjusted by variing the initial amount of virus 
that was applied to the cells. Between the selection rounds, viral pools were eventually 
amplified using 15cm dishes with 5x106 BLM seeded 24h post infection. Cells were 
preinfected with 2800 pfu/cell adenovirus 2 h prior to AAV infection and viral progeny 
harvested 48 h post infection. 
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Amplifications were performed on a 15 cm dish, using no more than GOI=100 for 
amplifications, to avoid uncoupling of genotype and phenotype through multiple infections of 
single cells. 
 
10.5.4 Immune escape selection protocol 
5x106 HeLa cells were seeded on 150 mm Petri-dishes 24 h before infection. Various amounts 
(0%; 5%, 33% or 50%) of human neutralizing serum and 100 viral particles per cell were 
incubated 24 h after seeding. Low GOIs and many cells were used increasing the possibility 
that efficient clones could really infect at least one cell while simultaneously reducing the 
chance of generating chimeric viruses with no correspondence between genotype and 
phenotype. The incubations were performed for 2 h at 37°C in a total volume of 15µl (filled 
up with PBS). The serum was obtained with informed consent from the Klinikum 
Großhadern, Munich, Germany, and tested for its ability to neutralize AAV-2 (Huttner et al. 
2003). 
Simultaneously, HeLa cells were preinfected with adenovirus (700 pfu/cell) in 10 ml of 
DMEM/0% FCS. After two hours, the adenovirus-containing medium was wasted and cells 
were infected with the AAV-library. 48 h post infection cells were collected by centrifugation 
and resuspended in 500 µl of lysis buffer (150 mM NaCl, 50 mM Tris-Cl, pH 8.5). Cells were 
lysed by three cycles of freeze/thaw and cell debris was removed by centrifugation. 
Adenovirus was heat inactivated (60°C, 30 min) and supernatant containing the viral progeny 
was applied to further selection rounds. After each round, viral DNA was extracted from 10μl 
of the lysate and genomic titer of progeny was monitored by qPCR using the “wtAAV 
genomic titration” protocol. Accordingly, a dilution of the viral progeny equaling GOI = 100 
was introduced into the next selection round.  
 
The selective pressure was increased in a selection by increasing the percentage of serum. In 
the first two selection rounds, the serum concentration was kept lower (33%) than in the 
following two (50%). 
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10.5.5 Infection assay (BLM cell specificity)  
A total of 4 × 104 BLM/Fibroblast cells were seeded in 48-well plates and infected 24 h later 
with same amounts of genomic particles of wt or capsid modified GFP expressing vectors. 
After 48 h, cells were harvested and GFP expression was measured by Cytofluorimetry 
analyzing at least 5000 cells. Target-to-noise ratios were obtained by dividing the percentage 
of infected BLM by the percentage of infected fibroblasts. To compare selectivity of the 
mutants with selectivity of wt, mutant target-to-noise ratios were divided by wt target-to-noise 
ratio. 
 
10.5.6 Infection assays (Immune escape mutants) 
2x104 HeLa cells were seeded in 48 well plates 24 h before infection. Identical numbers of 
transducing and total particles (6.5x108, adding A11 empty particles when needed) in the 
same volume (adding 40% iodixanol if needed) were incubated with serial dilutions (0,05%-
15% in PBS) of human serum or IVIG (Intratect©, a pooled human IgG stock) for 2 h at 37°C 
in a total volume of 20μl. Before addition to the cells, 100 μl of PBS was added to each 
sample. At least 5000 cells were analyzed by Cytofluorimetry 48 h post infection to determine 
the amount of GFP expressing cells.  
Mixture of full and empty particles with iodixanol was titrates after mixture by qPCR and 
ELISA assay. 
N50 was calculated using hill sigmoidal curve fit (origin 8):  
y = START + (END - START) * x^n  /  (k^n  +  x^n) 
(START: max. y-data, END: min. y-data, n=2, k=x at y50) 
 
10.5.7 Decoy assay 
For determination of the decoy effect of wt and mutant capsids, 2x104 HeLa cells were seeded 
in 48 well plates 24 h before infection. 105, 2x105 or 4x105 of either wt or mutant empty 
particles were added to104 wt genomic particles per cell. Incubation, infection and 
Cytofluorimetry were performed as described above (Infection Assays (Immune Escape 
Mutants)). 
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10.5.8 Heparin inhibition assay 
24 h prior to infection 2x104 HeLa cells per well were seeded in 48 well plates. 6x103 
genomic particles of wt or capsid modified GFP expressing vectors per cell (6x104genomic 
particles per cell for AAV1)  were incubated in a total volume of 500 μl of DMEM/10% FCS 
in the presence or absence of 1.7% (85 I.E./ml) soluble heparin (5000I.E./ml, B. Braun 
Melsungen AG, Germany) at 37°C for 30 min. 
This solution was then used to infect cells. 48 h post infection, the percentage of transduced 
cells was determined by Cytofluorimetry.
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12 Abbreviations 
Amino acids 
 
A   alanine 
C   cysteine 
D   aspartate 
E   glutamate 
F   phenylalanine 
G   glycine 
H   histidine 
I  isoleucine 
K   lysine 
L   leucine 
M   methionine 
N   asparagine 
P   proline 
Q   glutamine 
R   arginine 
S   serine 
T   threonine 
V   valine 
W   tryptophan 
Y   tyrosine 
 
Bases 
A   adenine 
C   cytosine 
G   guanine 
N  A, C, G or T 
S  C or G 
T   thymine 
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AAV   adeno-associated virus 
Ad   adenovirus 
bp   base pair 
CD   cluster of differentiation 
CFTR  cystic fibrosis transmembrane conductance regulator 
d   day 
DNA  deoxyribonucleic acid 
e.g.   for example 
ELISA  enzyme-linked immunosorbent assay 
FACS   fluorescence-activated cell sorting 
GFP   green fluorescent protein 
GOI   “genomicity of infection”; viral genomes applied per cell 
h   hour 
Hstk  herpes simplex thymidine kinase 
HSPG  heparan-sulfate proteoglycan 
I.E.  international units 
IgG  Immunoglobulin G 
IL   Interleukin 
ITR   inverted terminal repeat 
IVIG   intravenous immunoglobulin 
Kb  kilobases 
kDa   kilo Dalton 
min   minute 
µl  micro liter 
ml  milliliter 
N50  amount of serum needed to halve the number of transduced cells 
Nabs   neutralizing antibodies 
Nm  nanometer 
NPC   nuclear pore complex 
ORF   open reading frame 
pfu  plaque forming units 
qPCR  quantitative polymerase chain reaction 
RBS   Rep binding site 
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rpm   rounds per minute 
s   second 
TGF   transforming growth factor  
TLR   toll-like receptor 
TRS  terminal resolution site 
VP   viral protein 
w/o   without 
wt  wild typ
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